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ABSTRACT
MECHANISTIC CHARACTERIZATION OF THE 
MITOCHONDRIAL TYPE I DNA TOPOISOMERASE AND 
A STUDY OF GENES CONTAINING TYPE I DNA 
TOPOISOMERASE-RELATED DOMAINS
Jaydee Dones Cabral 
Old Dominion University 
and
Eastern Virginia Medical School 
2000
Director Dr. Frank J. Castora
The mitochondrial type I DNA topoisomerase (mt-topo I) serves an important 
function in the mitochondrion by relaxing mtDNA supercoils to allow for replication of 
the mitochondrial genome as well as for gene expression. The mt-topo I's role in essential 
processes, such as replication and transcription, makes it an ideal candidate as a target for 
antitumor or anti fungal drugs. To gain further insight into mt-topo I mechanism, a 
cleavage assay and drug inhibition studies were performed. As well, a search for the mt- 
topo I gene or genes containing type I topoisomerase-related domains was conducted. To 
characterize the mt-topo I mechanism, the 5’ or 3’ binding of the mt-topo I to cleaved 
DNA was assessed by electrophoresis on an agarose gel after treatment with and without 
proteinase K (PK). The results of the cleavage assay revealed that the mt-topo I formed a 
covalent linkage to the 5’ end of cleaved DNA In addition, drug inhibition studies were 
performed to aid in distinguishing between the mt-topo I and the nuclear type I 
topoisomerase (nu-topo I). In agreement with earlier work with the calf thymus mt-topoL, 
the calf liver mt-topo I was found to be slightly more sensitive to inhibition by dimethyl 
sulfoxide (DMSO) than was the nuclear enzyme. In an attempt to identify new drugs that 
might selectively inhibit the mt-topo I, a series of seven compounds with
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antifungal/antimicrobial activity were examined using standard DNA relaxation assays. 
One of these drugs, designated Cl, was found to inhibit the nuclear topo I but not the 
mitochondrial enzyme and thus might serve as a useful tool to discriminate between these 
enzymes. To search for genes containing type I topoisomerase-related domains, reverse 
transcriptase polymerase chain reaction (RT-PCR) was performed to amplify conserved 
eukaryotic and prokaryotic topoisomerase I domains using primers that were homologous 
to these conserved regions. An amplified topo-related fragment, 575-1, which possessed 
a 57% similarity to a topo II signature, 56% similarity to a prokaryotic type I topo 
signature, and no similarity to the known nu-topo I, as indicated by prositescan searches, 
was used as a probe to screen a human cDNA library and in a northern hybridization. 
Fragment 575-1 detected a large 9 kb message which was three times the size of known 
type I topoisomerase messages. Due to the large message size, a further investigation to 
compare 575-1 to known eukaryote type I topoisomerase species was performed using 
the computational biology program, MEME. The program MEME finds conserved 
motifs in a group of DNA sequences. An RT-PCR positive control nu-topo I fragment, 
designated 575-6, was detected and included in the MEME run. 575-6, matched motif 1 
out of 6 motifs identified by MEME. 575-1 contained none of six type I topoisomerase 
motifs identified. The program, Dnapars, revealed via an unrooted phyiogeny tree that 
575-1 was distantly related when compared to seven known eukaryotic type I 
topoisomerase species. In conclusion, the mt-topo I gene is fundamentally different from 
known eukaryotic type I topoisomerases. Degenerate primers developed from eukaryotic 
type I topoisomerase conserved domains were unable to amplify a region of the mt-topo I 
gene in RT-PCR reactions, although the known nu-topo I was detected.
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Topoisomerases are ubiquitous DNA-modifying enzymes found in prokaryotes, 
eukaryotes, viruses, and organelles, such as chloroplast and mitochondria (1-5). 
Topoisomerases catalyze a variety of DNA topology-altering reactions enabling them to 
effect many genetic processes. These processes include DNA replication (6,7), 
transcription (8,9), recombination (10,11), and transposition (12). They function by 
introducing or removing DNA superhelical turns, tying or untying DNA knots, and lastly, 
catenating or decatenating circular DNA by forming enzyme-bridged strand breaks for 
the passage of another strand (13).
There are two classes o f topoisomerase (topo), type I and type II. Type I 
topoisomerases (topi) cleave a single strand of DNA and pass the intact strand though the 
break before resealing. Type II topoisomerases (top2) are ATP-dependent, and cleave 
both DNA strands, passing the intact strand from the same or different molecule through 
the break before resealing. In both cases, the same four steps in mechanism prevail. 
First, the topoisomerase binds DNA Next, the DNA strand is broken. Subsequently, the 
strand is passed through the break, and finally, the strand is resealed. To date, all type I 
and type II topoisomerases studied have been found to be covalently linked to the cleaved 
DNA via a phosphotyrosine linkage (14-17).
Archives o f Biochemistry and Biophysics.
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Subgroups of the type I topoisomerase family exist (Table 1). The two 
subgroupsare monomeric, nonhomologous, and differ in the type of DNA adducts they 
form. The type LA topoisomerase subfamily exhibits a mechanism, homologous to 
bacterial type I topoisomerases, wherein the enzymes covalently link to the 5’ end of 
cleaved DNA. Members of the type LA family include E. Coli topo I and topo HI, 
eukaryotic topo ILL, and prokaryotic reverse gyrase (18). The type IB topoisomerase 
subfamily links to the 3’ ends of cleaved DNA. Members of the type IB family include 
eukaryotic topo I, prokaryotic topo V, and the poxvirus type I topoisomerases.
TABLE 1
Subgroups of Type I DNA Topoisomerases
LA IB
5’ covalent linkage 3’ covalent linkage
Relax negative supercoiled 
DNA
Relax negative and positive 
supercoiled DNA
Not inhibited by camptothecin Inhibited by camptothecin
Requires divalent cation Does not require divalent 
cation, but is stimulated in its 
presence
2 classes: Prokarvotic topo I 
(reverse gyrase), topo in  
(prokaryotes and eukaryotes)
Eukaryotic topo I (nuclear topo 
I), prokaryotic topo V, 
poxvirus type I, mitochondrial 
topo I (5’ or 3’ linkage?)
The type II topoisomerase family, on the other hand, shows a mechanism where 
during cleavage, a pair of tyrosines attack opposite strands of the DNA duplex and 
become covalently attached to the DNA through the 5’-phosphotyrosine linkage.
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Members of the type II topo family include the bacterial gyrase, yeast topoisomerase, and 
mammalian topoisomerases. £. coli DNA gyrase is a B2A2 heterotetramer whereas yeast 
topo II is a (BA)2  homodimer. The N-terminal region of the B region contains the ATP- 
binding and hydrolysis activities, while the A region contains the active-site tyrosine. 
Mammalian type II topoisomerases have two isoenzymes, Ha and 11$, that possess 
indistinguishable enzymatic properties. A subgroup of the type n  topoisomerase family 
also exists which is comprised of the bacterial topoisomerase IV (19).
In addition to subgroups within the type I topoisomerase family, there exist 
distinct biochemical differences between the prokaryote and eukaryote varieties overall. 
The prokaryote topoisomerase I has an absolute requirement for Mg2*, relaxes negative 
but not positive supercoils, is not inhibited by the anti-tumor plant alkaloid camptothecin, 
cleaves single stranded DNA, forms a phosphotyrosine linkage to 5’ end of DNA, and 
does not cleave relaxed DNA. The eukaryotic nuclear topoisomerase I (nu-topo I), on the 
other hand, is stimulated by but does not require Mg2*, relaxes both negative and positive 
supercoils, is inhibited by camptothecin, cleaves double and single stranded DNA, 
cleaves relaxed DNA, and forms a phosphotyrosine linkage to 3’ end of DNA (20,21).
Most mitochondrial type I topoisomerases (mt-topo) like their eukaryotic 
counterparts, do not require Mg2* but are stimulated in its presence, are able to relax 
positive and negative supercoils, and form phosphotyrosine linkages to DNA The yeast 
mt-topo I, unlike its nuclear counterpart, exhibits an absolute requirement for a divalent 
cation such as Mg2* or Ca2*. In addition, it is slightly more sensitive to monovalent salts, 
with optimal activity obtained in 50-100 mM KC1 (22).
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Other factors that distinguish the mt-topo I from the nuclear enzyme are 
differences in their MW, pH profile, thermal stability, chromatographic properties, 
sensitivity to dimethyl sulfoxide, ethidium bromide, and the trypanocidal agent berenil 
(23-25). In addition, the mt-topo I also yields a protease digestion pattern distinct from 
that of the nuclear enzyme (26). Although differences in these biochemical properties 
have been observed, they can not eliminate the possibility that the mt-topo I may be a 
degraded nu-topo I fragment It is unknown whether the mt-topo I phosphotyrosine 
linkage occurs at the 5’ or 3’ end. Determining the site of linkage may provide 
additional evidence to help delineate between the nu-topo I and the mt-topo I.
Interest in the discovery of a mt-topo was motivated by the fact that the 
mitochondrion possesses its own circular DNA consisting of 16569 nucleotide base pairs 
that define 13 polypeptides that are components of the respiratory chain, 22 transfer 
RNAs, and 2 ribosomal RNAs. Each mitochondrion contains 2 to 10 copies of mtDNA. 
In order to get expression of the mtDNA, the DNA must be exposed to replication and 
transcription machinery. The need for a swivel in front of the replication fork to remove 
supercoils led investigators to believe in the presence of some type of topoisomerase. 
The role of topoisomerases in eukaryotic DNA replication has been proven in studies 
investigating SV40 DNA in vitro (6), and in experiments dealing with the replication of 
kinetopiast DNA as found in trypanosomes (27). Topoisomerases also play a very 
important role in transcription as found in studies with ribosomal RNA genes and protein 
coding genes as demonstrated in yeasts (28), Tetrahymena (29), and Drosophila (30).
In terms of the mitochondrial type I topoisomerase, activity was detected for the 
first time in rat liver mitochondria in 1985 (31). Topoisomerase relaxation assays (fig. 4)
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
5
provided evidence for the ability of the mt-topo I to relax supercoiled plasmid DNA, 
lending strength to the argument of its participation in replication and transcription (32). 
Type I mt-topo activity has also been discovered in yeast (33), calf thymus and liver (34), 
human platelets (35), and human leukemia cells (36). Without the discovery of the mt- 
topo I gene, the question still remains whether the mt-topo I truly exists. Critics believe 
that nu-topo I contamination of mitochondrial extracts account for the observed activity. 
Isolating the mt-topo I gene would definitively confirm its existence.
The search for the mt-topo I gene occurs within the nuclear genome. 
Mitochondrial evolution is believed to have begun with endosymbiosis between respiring 
bacteria-like endosymbionts and pre-eukaryotic host cells (37, 38). The majority of 
mitochondrial proteins of animals are encoded by nuclear genes and imported into the 
organelle where they function under conditions that differ from those in the cytosol. 
Unfortunately, the large variety of proteins within the cytosolic and mitochondrial 
compartments have obscured the identification of traits specific for either population of 
proteins (39). Evaluation of amino-terminal residues of a collection of mitochondrial 
precursors have identified a few features that distinguish the amino termini of proteins 
destined for the mitochondrion: a nearly total absence of acidic amino acid residues; 
preponderance of arginine, serine, and leucine residues; and a segment with a large 
predicted helical hydrophobic moment (40). Due to the lack of an obvious pattern found 
in amino acid sequences of known mitochondrial leader peptides, the use of a 
mitochondrial localization signal as a probe to search for the mt-topo I was not feasible. 
Another approach was implemented which took advantage of new technology.
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Computational biology tools, however, did prove useful in looking for the mt- 
topo I gene and type I topo-related genes. The employment of computational biology 
tools was preferred over more traditional gene isolation methods for several reasons. The 
primary reason was the inability to obtain enough mt-topo I protein for use in amino acid 
sequencing. A second reason was to take advantage of the sequence information 
available on known type I topoisomerases for the development of primers and probes. As 
well, computational biology provided a quick means to characterize putative mt-topo I 
DNA fragments. Database search results could be obtained within minutes.
Computational biology research or bioinformatics is a recently developed 
discipline or tool of molecular biology, not appearing in the literature until around 
1991 (41). Bioinformatics has been described as the convergence of two technologies: the 
explosive growth of biotechnology and the paralleled growth in information technology 
(42). A nucleotide or protein sequence of interest can be used to search sequence 
databases. These similarity searches are akin to computer generated southern blots, a 
technique that detects DNA containing specific base sequences. A great deal can be 
learned from an uncharacterized string of DNA or protein sequence if it possesses 
significant sequence similarity to a well studied protein or protein domain. Protein 
searches performed with translated DNA sequence can be used to scan enzyme domain 
databases. As well, multiple sequence alignments and phylogeny trees can be developed 
to investigate the evolutionary relationship between known genes and genes containing 
similar domains. The use o f bioinformatics technology was critical in finding type I topo- 
related genes.
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Obtaining the mt-topo I gene would open doors to investigating cancer-related or 
mitochondrial disorder related research. The mt-topo I’s role in essential processes such 
as replication and transcription makes it an ideal candidate for antitumor drugs, in 
addition to possible implications in the defective expression of mtDNA. In terms of 
cancer research, investigators have looked at chemically inhibiting topoisomerase I in 
cancerous cells. Such antitumor drugs would interfere with essential cellular processes, 
eventually leading to cell death.
Currently, there are topoisomerase inhibitors being investigated for clinical use 
with different drugs displaying specificity for the type I or the type II topoisomerases. 
Camptothecin is a type I topoisomerase inhibitor. Clinical studies show that camptothecin 
(CPT) and some of its derivatives are active in both slowly and rapidly proliferating 
tumors. The lactone form of CPT functions by reversibly stabilizing the cleavable 
complex, formed after the covalent attachment of the topoisomerase to the DNA through 
a phosphotyrosine linkage, resulting in single strand breaks and inhibition of religation. 
These events arrest DNA synthesis that leads to the arrest of the cell cycle in the S-G2 
phase, which ultimately results in cell death. Other type I inhibitors include topotecan 
and CPT-11 (irontecan). Topotecan and CPT-11 are both semisynthetic analogs of the 
natural plant alkaloid, CPT, designed to be more water-soluble (43). Topotecan displays 
antineoplastic activity against refractory non-small cell lung cancer and ovarian cancer. 
CPT-11 is particularly active against a diverse group of tumors, including colon cancer, 
non-small cell lung cancer, cervical cancer, and non-Hodgkin’s lymphoma (44). CPT has 
also been found to inhibit the mitochondrial type I DNA topoisomerase from bovine liver 
(45).
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Type II inhibitors can be divided into two categories, nonintercalating drugs and 
intercalating drugs. Examples of nonintercalating topoisomerase H-interacting drugs 
include the epipodophyllotoxins, etoposide and teniposide. Structure-activity studies of 
epipodophyllotoxins derivatives confirmed that antileukemic effects and topoisomerase II 
interactions paralleled one another. DNA alkaline elution studies show that both 
etoposide and teniposide lead to DNA strand breaks. Etoposide has been shown to be 
clinically effective against small cell lung cancer and germ cell tumors of testicular 
origin. Teniposide’s clinical role was confined to acute lymphoblastic leukemia (46). 
Examples of topoisomerase II intercalators include m-AMSA (an acridine) (4), 
anthracyclines, ellipticenes, and adriamycin. Alkaline elution studies of the interaction of 
DNA with these agents documented a consistent association of DNA strand breaks with 
topoisomerase II. Anti-tumor activity of modest proportions have been noted against 
endometrial adenocarcinoma and breast cancer (47).
In addition to anticancer drugs, the contribution of mtDNA defects to tumor 
formation may be related to the misfunctioning of mt-topo I (48). More specifically, 
findings in the case o f chronic myelogenous leukemias, reveal the presence of complete 
and partial duplications of mtDNA (49). These unicircular dimers may be formed by an 
internal recombination event assisted by the mt-topo I.
As mentioned previously, topoisomerases are not only implicated in cancer- 
related diseases but in mitochondrial disorders as well. Mitochondrial disorders may be 
defined as primary, due to defects in nuclear DNA encoding for mitochondrial protein or 
in mitochondrial DNA (50), or they may be secondary, due to all other causes. Various 
subgroups of mitochondrial disorders can include defects related to fuel transport and
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metabolism, associated with disturbances in oxidative phosphorylation and mutations in 
mtDNA, and age-related degenerative diseases. In terms of the mt-topo I’s role in 
mitochondrial related disorders, disorders associated with mutated mtDNA and/or 
misexpressed mtDNA are of particular interest. A number of diseases with mutations in 
the mtDNA have been linked to dysfunction in electron transport (51). The following 
syndromes have been vital in learning more about mitochondrial medicine, Kearne-Sayre 
syndrome (KSS), chronic progressive external opthalmoplegia (CPEO), Pearson’s 
syndrome, Leigh disease, myoclonic epilepsy and ragged red fibers syndrome (MERFF), 
and mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes 
(MELAS). More specifically, partial duplications and deletions of mtDNA have been 
found in mitochondrial myopathies and Pearson’s Syndrome (52). These mutations may 
be explained by the production of defective mt-topo I (53). Defective mt-topo I can be 
implicated in a number of important cellular events which result in abnormal 
mitochondrial function. Some examples include expression of mtDNA regions that are 
normally not expressed, a lack of expression of regions that normally are expressed, 
defective mt-topo I’s that cleave mtDNA, but cannot ligate, or the ligation of incorrect 
strands resulting in an abnormal recombination event Future studies involving analysis 
of mt-topo I interfering with the normal processing of mtDNA and/or its gene products 
should be further investigated.
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STATEMENT OF PROBLEM
The overall goal of this study was to characterize the mechanism of type I 
mitochondrial DNA topoisomerase (mt-topo I) and to search for the mt-topo I gene or 
genes containing type I topoisomerase-related domains.
The specific aims of this proposal were:
(1) To search for the mt-topo I gene or genes containing type I topoisomerase- 
related domains, RNA was isolated from human placental tissue using a CsCl 
preparation. Reverse transcriptase polymerase chain reaction (RT-PCR) was then 
performed using primers homologous to conserved domains in type I topoisomerases 
found in eukaryotes and prokaryotes. These primers were used in various combinations 
under stringent conditions to favor more specific binding. PCR products were then 
sequenced, and the resulting sequence compared to sequence databases to aid in their 
identification. Any unique or uncharacterized RT-PCR sequence that possessed some 
topoisomerase homology was used as a radiolabeled probe to screen a human cDNA 
library in order to obtain the full-length mt-topo I gene. The unique sequence was also 
used to perform a northern blot for determination of message size.
(2) To characterize the relationship between known topoisomerase type I genes 
and genes containing topoisomerase type I-related domains multilevel consensus 
sequence analysis (MEME), and phylogeny tree (dnapars) programs were performed 
using a database of seven known eukaryotic type I topoisomerases and RT-PCR product 
sequences generated from type I topoisomerase conserved domain primer sets.
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(3) The determination of 5’ or 3’ binding of the mt-topo to cleaved DNA was 
assessed by electrophoresis on an agarose gel after treatment with and without proteinase 
K (PK).





E-C power supply by E-C Apparatus Corporation was used for agarose gel 
electrophoresis. MBP 3000D Electrophoresis power supply and DNA sequencing system 
by EBI were used for DNA sequencing. Stratagene UY stratalinker 1800 was used for 
DNA transfer. UV transilluminator was from UVP, Inc. The UV spectrophotometer used 
was a Beckmen model DU-50. The camera system was an MP-4 Land camera from 
Polaroid. A Savant speed-vac concentrator connected to a Savant refhgerated 
condensation trap was used. A Biorad model 83 slab dryer was used for gel drying. The 
thermal cycler used for PCR was a Bamstead Thermolyne Temp Tronic. A Labconco 
purifier Class II Safety cabinet was used for culture work. All micro fuges were from 
Beckmen. All balances were from Mettler.
MATERIALS
Plasmid pUC19 DNA was isolated from HBI01 cells harboring the plasmid by 
lysing the cells with alkaline-SDS followed by cesium chloride centrifugation in the 
presence of ethidium bromide (32). Mitochondrial DNA was recovered from purified 
bovine liver mitoplasts. Taq DNA polymerase, T4 polynucleotide kinase, and Proteinase 
K were purchased from Promega. Random primer labeling system was from Gibco BRL. 
Various restriction enzymes, pGEM-T Vector System, helper phage R408, and finol 
DNA sequencing system were purchased from Promega. DNA primers were synthesized
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by Integrated DNA Technologies, Inc. Camptothecin, cellulose phosphate, 
hydroxyapatite, double stranded DNA cellulose, and Sigmacote were from Sigma. All 
radioactive isotopes were from NEN. DNA grade agarose, acrylamide, and bis- 
acrylamide were from Fisher. All other chemicals were of analytical grade or higher. 
For PCR purification Prep-a-gene purification kits from Biorad were used. The Genius 
Chemiluminescent Detection kit was from Boehringer Mannheim. Polaroid type 55 film 
and Fuji RX autoradiography film were from VWR.
METHODS
Human Placental Tissue RNA Isolation
A CsCl preparation was used as follows. Flash frozen human placental tissue was 
homogenized using a polytron in a guanidinium isothiocyanate and f$-mercaptoethanoi 
solution. The sample was spun and the supernatant decanted into new sterile, 
polypropylene tubes. The pellet was discarded. A chloroform /isoamyl alcohol (24:1) 
solution was added to the supernatant, mixed, and then spun. The aqueous layer was 
transferred to a new tube. The solution was pulled back and forth several times with a 
syringe in order to shear the DNA. The sample was then layered on top of a CsCl 
gradient solution (0.96 g/ml), and centrifuged at 39,000 rpm for 21 hours. The 
supernatant was removed and discarded. A clear, white pellet of RNA remained. 
Sodium acetate was added to resuspend the RNA. RNA samples were quantitated and 
stored in a sodium acetate/ethanol solution at -20°C. Samples were analyzed 
spectrophotometrically (260:280 ratio) and visualized via formaldehyde gels. RNase 
contamination of tubes, buffers, etc. was kept at a minimum to prevent degradation. All
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aqueous solutions were made with 0.1% diethylpyrocarbonate (DEPC) treated water. All 
glassware was oven baked overnight at 200°C. Pipet tips were autoclaved prior to use. 
Gel boxes were soaked in 3% hydrogen peroxide solution for 3 hours. Powder-free 
gloves were w >m at all times when working with RNA in a specified RNA work zone. 
Probe and Primer Design
a. mt-topo I gene isolation- DNA was amplified from human RNA using primers 
homologous to type I topoisomerase conserved regions from various eukaryotic or 
prokaryotic species. There exist four highly conserved domains, A, B, C, and D in 
eukaryotic topo genes (fig. 1) (54). Primers were chosen from areas just outside these 
conserved regions using DNA sequences that represent codons with minimum 
degeneracy. Topoisomerase I gene sequences from Drosophila, cow, rat, frog, and human 
were compared to determine the most frequently used base pairs in degenerate codons. 
Degenerate primer sets were designed to represent each possible permutation in a 
selected conserved region. Primers were used in different combinations under stringent 
conditions to favor more specific binding (Table 2 and 4). Prokaryotic primers were also 
used. Prokaryotic primers were considered due to the fact that the mt-topo I resembled 
the prokaryotic type I topoisomerase in its mechanism of action, exhibiting 5’ 
phosphotyrosine linkage to cleaved DNA verses nu-topo I’s 3’ phosphotyrosine linkage. 
In addition, the suggestion of prokaryote homology was not unheard of due to the 
endosymbiont theory, which suggests a prokaryotic origin of the mitochondrion (55). 
Lastly, an exact human nu-topo I primer set was used to serve as a RT-PCR positive 
control.













FIG. 1. Four conserved domains in topo I eukaryotic species.
TABLE 2
RT-PCR primers
Eukaryotic Degenerate topo I primers
Name Sequence
Region Al 
Region C l 
Region C r 
Region D r
5’ AAR TGG AAA YGG TGS SA 3’ 
5’ ATG GAR MAC AAG SAG SS 3’ 
5’ SSC TSC TTG TKY TGC AT 3’
5’ YCM YAY TTY TTR CAM CM 3’
S= C,G; K= G,T; M= A,C; R= A.G; Y= T,C
Exact Human nu-topo I primers
Name Sequence
Region Al 
Region C r 
Region D r
5’ AAG TGG AAA TGG TGG GA 3’ 
5’ GGC TGC TTG TTC TCC AT 3’ 
5’ CCC CAC TTC TTG CAC CA 3 ’




5’ GAG TCG CCC GCA AAA GC 3 ’ 
5’ TTC CAT CTG CGC GGT GAA 3’
b. mt-topo II gene isolation- Topoisomerase type II probes were designed in a similar 
manner as the type I topo primers in that they were derived from conserved regions. The 
probes were selected from conserved sequences from Saccharomyces cerevisiae,
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Schizosaccharomyces pombe, Drosophila melanogaster, and Homo sapien. Topo II 




A 5’ TTTIGC ACC RTTICI ACC IGT 3’
B 5’ ATCTTG ATC IGT CAT RAT CAT 3’
C 5’ GAIGTA CCT ARA CCT TTR TAR TAT TT 3’
D 5’ CAT TTICIT TGA CCT GGT TT 3 ’
E 5’ ACC IGT ACC RAT ACC TTC IGC ACC RTT 3’
Exact topo II primers were generated using the known human topo II sequence. 
The software, Primer Design, was used to generate three primer sets at the 5’, middle, 
and 3’ portion of the human topo II gene. The exact topo II primers were used in RT- 
PCR as well as in plaque PCR. The expected size nu-topo II fragments generated from 
each primer set are as follows: 517 bp (5’ primer set), 314 bp (mid primer set), and 787 




5’l 5’ TGC ACT AAT GGT CAG AAG AG 3 ’
5’r 5’ GTA ACC GAC ACC ATA ACA TC 3’
midL 5’ GGG TAC TAT TGA AGA ACT GG 3’
midR 5’ GAG TGT ACG TTG AGA TAC CA 3’
3 ’l 5’ TCA GAA TCA GAT AGG AGC AG 3’
3’r 5’ GGA CTT CGA GAA TTG AAG GA 3’
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RT-PCR
a. RT (Reverse TranscriptaseV Human liver mRNA (100 ng, Origene Technologies, Inc.) 
and right primers (Drev, Crev) were heated at 70°C, then chilled on ice. The following 
components were added: AMV RT 10X reaction buffer, 10 mM dNTP mix, RNasin 
ribonuclease inhibitor (40 u/pl), 100 mM oligo(dT)i5, AMV-RT (5 u/pl), and DEPC- 
treated (0.1%) water. In order to track the reaction, one-fifth of the reaction mixture was 
placed into another tube containing [a-32P]dCTP (3,000 pCi/mmol). The radioactive and 
nonradioactive samples were then incubated at 37°C for 2 hours, placed on ice, with the 
subsequent addition of EDTA. EDTA was added to chelate the RT enzyme and inhibit 
its function. In addition to the original sample, two negative control samples were 
analogously performed, one containing all components except the RNA; the other, 
containing all components except the AMV-RT. A southern blot was also performed to 
confirm that DNA synthesis had occurred. Unlabeled RT sample was run on a 1% 
agarose gel, the DNA transferred to a nylon membrane, and the membrane hybridized 
with the radiolabeled primers A l and C l. Primers were 5’ end labeled using [y-32P]ATP 
(3,000 pCi/mmol) and T4 polynucleotide kinase (5 units). Hybridization of these probes 
to the DNA showed that the DNA strands synthesized in the RT are long enough to 
produce the expected PCR products from the nuclear topoisomerase gene, and, 
presumably, from a putative homologous mt-topo I gene.
b. PCR- The above reaction mixtures were ethanol precipitated overnight at -20°C. The 
samples were then spun at 4°C for 30 minutes. The supernatant was removed and the 
pellets resuspended in 20 pi of water. A standard PCR reaction mixture (10X RT-PCR
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buffer, 20-400pM forward and reverse primers, 2 units Taq polymerase) was used




Annealing temperatures and [Mg2-*! varied depending on the primer set used 
(Table 5). Moles of DNA synthesized from the RT were calculated using the specific 
activity of the radiolabel, the conversion factor 1 Ci is equivalent to 2.2 X 1012 cpm 
(counts per minute), and the cpm obtained from spotting a one microliter portion of the 
labeled RT products on Whatman DE-81 disks. The disks were washed 6 times with a 
sodium phosphate buffer, followed by 2 washes with water, and 2 washes with ethanol. 
The dried disks were then placed in a vial containing 3 mL of scintillant and counted. In 
addition, the labeled portion of the RT mixture was run on a 1% agarose gel for 5 hours 
at 60 volts in IX TBE (0.089 M Tris base, 0.089 M boric add, 20 pM EDTA, pH 8.0) 
buffer, dried under vacuum at 60°C, and exposed overnight to film at -70°C. PCR 
products were analyzed on 1% agarose gels stained with ethidium bromide (10 pg/pl).
TABLE 5
PCR parameters for each primer set
Primer set Annealing T (°C) rMgz+l(mM)
Deg. A-C 57 2
Deg. C-D 56 3
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Plaque PCR
Plaque PCR was used to determine if positives generated from Agtll cDNA library 
screens contained conserved eukaryotic or prokaryotic topo regions. Potentially positive 
plaques were cored out using a pasteur pipet and then placed in SM buffer (10 M NaCl, 
8 mM MgSO-t, 50 mM Tris, 0.01% gelatin) . Negative plaques were also cored out to 
serve as negative controls to eliminate PCR products generated from the Agtll vector 
itself. Ten pL of the SM mixture was placed in a 0.5 pL microfuge tube, boiled for 5 
minutes, and then placed on ice. One ml of the denatured SM mixture was used as the 
DNA template source for a standard PCR reaction.
The primers shown in Table 6 were used to screen potential positives from the 
Agtl I cDNA screen using 575-1 as the probe. 575-1 was a RT-PCR product generated 
from the eukaryotic degenerate topo I primer set Cl and Drev. 575-1lr represent primers 




575-1L 5’ CTG TAT CCA GCA CAC CAC TG 3’
575-1r 5’ TCC CAG TTT CTT AGC TTT GA 3’
pGEM Vector Cloning
PCR products were purified using Biorad Prep-a-Gene. Purity was assessed by gel 
electrophoresis and ethidium bromide (0.1 ng/ml) staining. For the ligation reaction the 
following components were mixed, then incubated at room temperature for 1 hour or 
overnight at 4°C: 2X Rapid Ligation Buffer, pGEM-T vector, PCR product, T4 DNA
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
20
ligase, and water. For the transformation, two LB/ampicillin (AMP, 100 pg/mI)/IPTG 
(0.5 mM)/X-Gal (800 pg/ml) plates per ligation reaction were equilibrated to room 
temperature prior to plating. An aliquot of the ligation reaction was added to thawed 
JM109 High Efficiency Competent Cells, mixed, and placed on ice for 20 minutes. The 
cells were then heat-shocked for 50 seconds at 42°C and placed on ice for 2 minutes. 
SOC medium (for 100 ml solution: 2.0g bacto-tryptone, 0.5g bacto-yeast extract, 10 mM 
NaCl, 2.5 mM KC1, 20mM filter-sterilized Mg2+, 20 mM filter-sterilized glucose) was 
added to the transformation mix and incubated for 1.5 hours at 37°C with shaking. The 
transformation culture was plated using LB-agar onto duplicate plates. Plates were 
incubated overnight at 37°C.
a. rapid plasmid preparation- Isolation of plasmid DNA was performed using the 
Alkaline Lysis method. Three milliliters of LB media-AMP (for 1 liter solution: add 10 g 
agar bacto-tryptone, 5 g bacto-yeast extract, 5 g NaCl, adjust pH to 7.0 with NaOH, 
autoclave, cool to 50°C, and add AMP to final concentration of 100 pg/ml) was 
inoculated with a single bacterial colony and shaken overnight at 37°C. The overnight 
culture was then collected by spinning down the bacteria for 3 minutes in a 4°C 
microfuge at maximum speed. The supernatant was decanted, the pellet resuspended in 
4°C Solution I (50 mM glucose, 10 mM EDTA, 25 mM Tris-Cl pH 8.0), and incubated at 
room temperature for 5 minutes. Freshly prepared Solution II (0.2 N NaOH, 1% SDS) 
was added, mixed by inversion, and incubated on ice for 5 minutes. Ice-cold potassium 
acetate (Solution in, 0.3 M) was added, the sample vortexed, and incubated on ice for 5 
minutes. Samples were centrifuged and the supernatant transferred to a new tube. 
Solution IV (phenol/chloroform/isoamyl alcohol/1% hydroxyquinoline) was added, the
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samples vortexed and spun in a microfuge for 2 minutes at maximum speed. The 
aqueous supernatant was transferred to a new tube and ethanol precipitated overnight at -
20°C.
b. ssDNA isolation- For induction of ssDNA production, recombinants were infected 
with helper phage R408. The plasmid enters the fl replication mode, and the resulting 
ssDNA is exported as an encapsulated virus-like particle. The ssDNA was purified from 
the supernatant using a simple precipitation and extraction procedure (Promega Protocols 
and Application Guide, catalog #P1610). An overnight culture of the recombinants was 
prepared by picking colonies off M9 plates, inoculating in 1 ml of LB-AMP media, and 
incubated at 37°C with vigorous shaking. The next morning, 25 ml of LB-AMP media 
was inoculated with 0.5 ml of the overnight culture, followed by a 30 minute incubation 
at 37°C. The culture was then infected with helper phage at a multiplicity of infection of 
10 (10 helper phage particles per cell) and allowed to shake for an additional 6 hours at 
37°C. The supernatant was harvested by pelleting the cells at 12,000 x g for 15 minutes. 
The supernatant was poured into a fresh tube and centrifuged again for 15 minutes. The 
phage were precipitated by adding phage precipitation solution (3.75 M Ammonium 
acetate pH 7.5, 20% PEG 6000) and incubating overnight at 4°C. The sample was 
centrifuged, the pellet thoroughly drained, and resuspended in 400 pi TE buffer (10 mM 
Tris-Cl, pH8.0, 1 MM EDTA, pH 8.0). To lyse the phage, 400 pi of a 24:1 
chlorofomdsoamyl alcohol solution was added, vortexed for 1 minute, and centrifuged at
12,000 x g for 5 minutes. The upper, aqueous phase was transferred to a fresh tube, 400 
pi of 25:24:1 phenol/chloroform/isoamyl alcohol solution was added, the mixture was 
vortexed for 1 minute, and centrifuged at 12,000 x g for 5 minutes. This phenol
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extraction was repeated twice. The upper, aqueous phase was transferred to a fresh tube. 
The ssDNA was precipitated by overnight ethanol precipitation (add 0.5 volume of 7.5 M 
ammonium acetate, 2 volumes of 100% ethanol, mix, and store at -20°C overnight). To 
recover the ssDNA, the sample was centrifuged at 12,000 x g for 5 minutes, the 
supernatant removed, the pellet was rinsed with 70% ethanol, and the pellet was allowed 
to air dry. The ssDNA was resuspended in 20 pi nuclease-free CUH2O. The amount of 
DNA can be estimated by agarose gel electrophoresis and ethidium bromide staining. 
Two major bands were usually seen: helper phage and ssDNA.
Cycle Sequencing
Promega’s find DNA Cycle Sequencing System was designed for thermal cycle 
sequencing, which incorporates Sanger’s dideoxy sequencing method and utilization of 
PCR (67). Purified PCR products or subclones were sequenced using nanogram 
quantities of template. Sequencing reactions included a Taq DNA polymerase (5 units) 
to synthesize a DNA strand complimentary to the DNA template, a short synthetic 
nucleotide primer which was homologous to a portion of the template and was 5’ end 
labeled using [y-32P]ATP (3,000 Ci/tnmol) and T4 polynucleotide kinase (5 units), and 2 
pi of each dideoxynucleoside triphosphates (ddNTPs) that randomly terminated chain 
elongation when incorporated at the end of a growing chain. The sequencing reaction 
was then placed in a thermocycler using a thermal cycle sequencing profile. The chosen 
profile was designed for primers <24 bases or with a GC-content <50%. The sequencing 
profile was as follows:
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35 cycles total, then 4°C 
After the thermocycling program was complete, 3 pi of finol sequencing stop 
solution was added to 6|il of reaction mix. The sequencing products were then loaded in 
three intervals on an 8% polyacrylamide gel for 2 hours at 65 watts each in IX TBE 
running buffer. The fragments, having been separated in parallel lanes in the gel, gave a 
pattern of radioactive DNA bands from which the DNA sequence was read. The 
polyacrylamide gel was exposed overnight to film at -70'C . The sequence was 
compared to the Genbank database in order to determine its originality and approximate 
position relative to the full length nu-topo I gene.
a. 5’end-label primers- The following were combined in a microcentrifuge tube: 10 pmol 
primer (Table 2, 4,6), 10 pmol [y-32P] labeled ATP, lp l 10X T4 Polynucleotide Kinase 
buffer, T4 Polynucleotide Kinase (5 units), and sterile water. The mixture was incubated 
at 37 °C for 30 minutes and the kinase inactivated at 90 *C for 2 minutes. The end- 
labeled primers were stored at -20* C.
b. single-stranded DNA templates- ssDNA templates were synthesized as previously 
described. ssDNA templates were used in the hopes of generating more legible sequence.
c. double-stranded DNA templates- Double-stranded DNA was generated as previously 
described in the rapid plasmid preparation.
Bioinformatics Programs
A variety of bioinformatics programs were used. They included basic similarity 
searches, multilevel consensus analysis, and phytogenies estimations. Multilevel 
consensus analysis, multiple alignments, and phytogenies estimations were performed
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using a worldwide web based system for DNA and protein sequence analysis called 
Bionavigator (56).
a. similarity searches- Similarity searches were performed in order to compare new 
sequence against all other known sequences in the hopes of deducing its function and/or 
identity. A variety of search programs available via the internet were used to scan DNA 
and protein databases. Examples of programs used were BLASTn (Basic Local 
Alignment Tool), BLASTp, BLASTx, tBLASTx, PROSITESCAN, and LALIGN. 
BLASTn, BLASTx, and tBLASTx were designed for nucleotide sequence queries. 
BLASTp was designed for protein sequence queries (57-61). PROSITESCAN was used 
to aid in the identification of uncharacterized protein sequence by searching for similarity 
to core patterns of known protein families (90). LALIGN was used to find the best local 
alignments between two sequences (62).
b. MEME (Multilevel Consensus Analysis)- Multilevel consensus sequence analysis 
(MEME) (63) uses the method of Bailey and Elkan (64) to find conserved motifs in a 
group of unaligned sequences. By default, the program assumes each motif occurs only 
once in each sequence in the search set The resulting motifs are output as profiles. A 
profile is a logs-odd matrix used to judge how well an unknown sequence segment 
matches the motif. A score is assigned to quantify the relationship of each sequence 
relative to the motif found. Minimum width of motifs to search for was 8 nucleotides and 
the maximum width of motifs was set at 57 nucleotides. The maximum width was set at 
57 due to the fact that the eukaryotic topo I active site is 19 aa or 57 nucleotides long.
c. dnapars- Dnapars estimates phytogenies by the parsimony method using nucleic acid 
sequence (65, 66). The method of Fitch (67) is used to count the number of changes of
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base needed on a given tree. The assumptions of this method are that each site evolves 
independently, different lineages evolve independently, the probability of a base 
substitution is small over the lengths of time involved in a branch of a phylogeny, the 
expected amounts of change in different branches of the phylogeny do not vary by so 
much that the two changes in a high-rate branch are more probable than one change in a 
Iow-rate branch, and the expected amounts of change do not vary enough among sites 
that two changes in one site are more probable than one change in another. Change from 
an occupied site to a deletion is one change. Reversion from a deletion to an occupied 
site is allowed and is also counted as one change. This in effect assumes that a deletion 
N bases long is N separate events (68). Phylogeny trees were viewed using the software 
Tree View (69).
d. ClustalWf accurate)- The program ClustalW (accurate) is used for multiple alignment 
of nucleotide or protein sequences. Pairwise similarity scores are calculated from slow, 
accurate, global alignments. These initial alignments are re-scored to give percent 
identity scores. Percent identity scores can then be converted to distances for phylogeny 
trees which are used to guide the final alignment, ie. sequence alignment results of 
ClustalW are used as input in the dnapars program (70).
Northern Hybridization
Two different protocols were used in northern blotting experiments:
a. biotinvlated probe- Total human liver RNA purchased from Origene Technologies, Inc. 
was run on a 1.2% formaldehyde/agarose gel at 50 volts for 2 hours. The RNA was 
transferred to a Magnacharge nylon transfer membrane (MSI, Inc.) via capillary action. 
The RNA was UV linked to the membrane by using a UV Stratalinker set at 120,000
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|jJ/cm2 for 30 seconds. The membrane was prehybridized at 42 “C for 1 hour, followed 
by an overnight hybridization at the same temperature in a mixture of Ambion’s 
Ultrahyb™ Ultrasensitive hybridization buffer and 50 ng/ml biotinylated probe RNA or 
DNA. The membrane was washed as follows before detected as described below: one 5 
minute wash at room temperature (R.T.) in wash 1 [2X SSC (0.3 M NaCl, 0.03 M 
Na3citrate-2H20, adjust pH to 7.0 with HC1)/0.1% SDS], one 5 minute wash at R.T. in 
wash 2 (0.2X SSC/0.1% SDS), one 5 minute wash at 42*C in wash 1, one 5 minute wash 
at 42 *C in wash 2, and a final wash in 2X SSC.
b. radiolabeled DNA probe- Human liver mRNA purchased from Clontech was run on a 
1.5% formaldehyde/agarose gel at 100 volts until the sample entered the gel, then at 22 
volts overnight. The electrophoresis was stopped when the dye front reached the end of 
the gel. The RNA was transferred to a neutral nylon transfer membrane (MSI, Inc.) via 
capillary action. The RNA was UV linked to the membrane by using a Stratalinker at
120,000 pJ/cm2 for 30 seconds. The membrane was prehybridized at 42*C for 1.5 hours 
followed by an overnight hybridization at the same temperature in Ambion’s Ultrahyb™ 
Ultrasensitive hybridization buffer and 83 ng total random primer labeled DNA. The 
probe was radiolabeled using Promega’s Prime-a-gene labeling system and [a-32P] dCTP 
(3,000 Ci/mmol). The membrane was washed as follows before being wrapped in saran 
and exposed overnight to film at -70°C with an intensifying screen: one wash for 30 
seconds at room temperature (R.T.) in wash 1 (IX SSC/0.1% SDS), one 5 minute wash at 
R.T. in wash 1 with gentle shaking, and two 10 minute washes in wash 2 (0.25X 
SSC/0.1% SDS) at 42 *C.
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Transcription Synthesis, Labeling, and Detection
a. transcription synthesis- RNA probes were synthesized using Ambion’s MAXIScript™ 
SP6/T7 In vitro transcription kit The following transcription reaction was assembled at 
room temperature: add nuclease-free water to a 20 pi final reaction volume, Ipg DNA 
template, 2 pi 10X Transcription buffer, 1 pi each of 10 mM ATP, CTP, GTP, UTP, and 2 
pi RNA polymerase. The mixture was incubated for I hour at 37°C. To remove template 
DNA, 1 pi DNase 1 was added, then the mixture was incubated at 37°C for 15 minutes. 
To stop the reaction, 1 pi Of 0.5M EDTA was added. Free nucleotides were removed by 
precipitation with ammonium acetate (add one-tenth volume 5.0 M) and ethanol (2 
volumes 100%). The solution was chilled at -20°C for 30 minutes or longer, spun for 15 
minutes at maximum speed in a 4°C microcentrifuge. The supernatant was discarded and 
the pellet was washed once with 70% ethanol. The pellet was resuspended in 50 pi of 
DEPC-water. The RNA probe was stored in 5 pi aliquots at -70°C.
b. labeling- Probes were biotinylated using Ambion’s BrightStar™ Psoralen-Biotin 
nonisotopic labeling kit. To label 0.5 pg of RNA in a 10 pi reaction, a clean, non-coated 
microtiter plate was placed on an ice bath. The following steps were performed in 
reduced light. One pi of Psoralen-Biotin reagent was added to 10 pi of RNA sample, 
mixed, and transferred to a well of the microtiter plate. A 365 nm UV light source was 
placed directly on the plate over the sample and irradiated for 45 minutes. The sample 
was diluted to 100 pi by adding 89 pi of IX TE. The mixture was transferred to a clean 
microcentrifuge tube. Two hundred pi o f n-butanol was added. The sample was then 
vortexed for 1 minute and centrifuged for I minute at 7,000 x g. The n-butanol layer was 
removed with a pipet The RNA probe can be stored at -20°C for short term storage or at
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-80°C for long term storage. DNA probes were 5’ end labeled using T4 PNK and [y-32P] 
ATP.
c. detection- After the northern hybridization was performed, Ambion’s BrightStar™ 
Biodetect™ kit was used to detect the biotinylated probe. The positively-charged nylon 
membrane was washed twice for 5 minutes each in IX wash buffer (use I ml/cm2), was 
washed twice for 5 minutes each in blocking buffer (use 0.5 ml/cm2), was washed once 
for 30 minutes in blocking buffer (use 1 ml/cm2), and was washed once for 10 minutes in 
conjugate solution (10 ml blocking buffer plus 1 pi streptavidin-alkaline phosphatase 
conjugate/100 cm2). The membrane was then washed once for 10 minutes in blocking 
buffer (use 0.5 ml/cm2), washed three times for 5 minutes each in IX wash buffer (use 1 
ml/cm2), washed two times for 2 minutes each in IX assay buffer (use 0.5 ml/cm2), and 
then washed once for 5 minutes in CDP-Star™ (use 5 ml/cm2). The excess 
chemiluminescent reagent was shaken off, the membrane wrapped in plastic wrap, and 
exposed to film at room temperature for 2 hours. 
cDNA Library Screen
A unique sequence was used as a radiolabeled probe to screen a Xgtl 1 cDNA 
library from human fetal liver tissue (ATCC). The cDNA library from human fetal liver 
tissue was selected because young, developing cells are mitochondria-rich; therefore, 
possessing a high amount of mt-topo I. The first step in the nucleic acid hybridization 
screening was to grow large numbers of the recombinant phage in our library on agar 
plates. In plating the bacteriophage the titer of the cDNA library was determined by 
serial dilution. The recombinant phage and plating bacteria, LE392 E. Coli cells, were 
then mixed in a culture tube and incubated at 37 *C. Top agar was added to the culture
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tube and transferred to LB plates. The plates were incubated at 37*C until the plaques 
covered the plate but were not confluent They were then incubated at 4* C for 1 hour 
before applying filters. To transfer to nitrocellulose filters, the filters were laid down, 
and left on the plates for a few minutes. The filter was removed from the plate and 
allowed to dry face up on the bench top. Duplicate lifts were obtained to eliminate false 
positives due to nonspecific binding. To denature the DNA, the filters were immersed 
using blunt-end forceps in the following solutions in the order shown using shallow trays: 
1 minute wash in 0.5 M NaOH/1.5 M NaCl, 5 minute wash in 0.4 M Tris-HCl, pH 7.6/2X 
SSC, and a final rinse in 2X SSC for 2 minutes. The filters were then dried overnight in 
an oven at 420 C. Filters were stored at room temperature until needed for hybridization. 
The filters were then incubated overnight with the unique sequence radiolabeled probe at 
a hybridization temperature of 65 ° C. After incubation, the filters were rinsed with low 
stringency wash buffer followed by a washing with high stringency wash buffer.
The number of plaques that were screened in order to get a 99% probability of 
finding the mt-topo I gene was obtained using the following equation, To
simplify the equation, we can say that e'R = 0.01 because there is a 1% chance that the 
mt-topo gene will not be found. Solving the equation for R, gives R= 4.6. Since a 
typical mammalian cell contains 160,000 mRNAs, by multiplying R with the number of 
messages, I needed to screen 736,000 plaques in order to get a 99% probability of finding 
the mt-topo I gene. Filters were exposed to film with an intensifier for a few hours at - 
70 “C when using fresh radiolabel. As the radioactivity of the 32P-label decreased over 
time, I increased the length of time the film was exposed to the filter.
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a. probes- Degenerate primers that were developed for RT-PCR and topo II probes, as 
previously described in tables 2 and 3, were used to screen the cDNA library. RT-PCR 
products of interest, synthesized from topo I degenerate primers, were also used as 
probes.
b. phage plate stocks- Phage stocks of putative positives from the tertiary cDNA screen 
were made in the following manner Phage (105 pfii) were mixed with 0.1 mL of 
exponentially growing plating bacteria. The mixture was incubated for 20 minutes at 
37°C to allow phage to adhere to the E. Coli cells (LE392). Three mL of top agarose (per 
liter: 10 g tryptone, 8 g NaCl, 6 g agarose, autoclave) at 55°C was added, mixed, and 
poured onto a labeled 85-mm plate containing 30 mL of hardened, dry LB/0.2% maltose. 
The plates were inverted and incubated for 8-12 hours, until lysis was confluent The 
plate was inverted, 5mL SM buffer was added, and the plates stored at 4°C for several 
hours with intermittent gentle shaking. With a sterile pasteur pipet the SM buffer was 
harvested. Fresh SM buffer (1 ml) was added and the plate was stored for 15 minutes in 
a tilted position at 4°C to allow all the fluid to drain to one area. Again, the SM buffer 
was removed and combined with the first harvest. The plate was discarded. One mL of 
chloroform was added to the pooled SM, vortexed, and centrifuged 4000 x g  for 10 
minutes at 4°C. The supernatant was recovered and chloroform added to 0.3% final 
concentration. The titer of the bacteriophage was determined by serial dilution. The titer 
was determined to be 10I0pfu/mL. Phage were stored at 4°C.
Fluorescence In Situ Hybridization
The putative mt-topo I clone was amplified to generate large quantities of DNA. 
This was done by RT-PCR amplifying the putative mt-topo I gene or genes containing
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topoisomerase domains by using degenerate primers developed from conserved 
topoisomerase domains. The amplified RT-PCR products were then random primer 
labeled (Gibco) with digoxigenin (DIG: 53,20[22]-cardenolide-3fJ,12$,14-triol;
3 (3,12 fi, 14-trihycLroxy-5 (5, 20[22]-cardenolide). The DIG labeled DNA and Cot-1 DNA 
(100 pg/ml) were ethanol precipitated and resuspended in hybridization mix (50% 
formamide, 2X SSC, 10% dextran sulfate, pH 7.0). To enable specific hybridization to 
the chromosomal target site, the probe was denatured together with an excess of 
unlabeled Cot-1 DNA. Cot-1 DNA was used to suppress unspecific hybridization to 
human repetitive sequences. Leukocyte cells were denatured at 72 * C in 70% formamide 
and 2X SSC. Probes were denatured at 72* C for 5 minutes. Hybridization was carried 
out at 37° C for approximately 20 hours before washing. Cytochemical detection was 
performed using FITC-avidin and biotinylated antiavidin amplification (Vector 
Laboratory, Burlingame, CA). Probe sequences that bound with the greatest homology 
should withstand more stringent washing than those that bound less closely matched 
sequences (91). Finally, slides were counterstained with DAPI (4\6-diamidine-2’- 
phenylinodole dihydrochloride), mounted in antifade medium (VectaShield), and viewed 
under a Zeiss Axioscope microscope. Computer based image collection and 
enhancement were used to compensate for reduced signal intensity. The appearance of 
hybridization signals on slides of specific chromosomes should locate the topoisomerase 
domain containing genes.
3 ' Rapid Amplification o f cDNA Ends
V  Rapid amplification of cDNA ends (RACE) system (Life Technologies™) was 
used to amplify the 3’ end mRNA of 575-1. This system is useful for rapid amplification
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of cDNA ends (RACE) and anchored PCR between a defined point within mRNA and 
the 3’ poly(A) end (72, 73). First strand cDNA synthesis and amplification o f the target 
cDNA were performed as directed by the 3’ RACE instruction manual. To generate first 
strand cDNA, 50 ng of human liver poly(A)+ RNA, DEPC water, and 500 nM adapter 
primer were combined in a microcentrifuge tube. The contents were heated to 70°C for 
10 minutes and chilled on ice for 1 minute. Following a brief spin in a microcentrifuge 
set at maximum speed, 10 X PCR buffer, 2.5 mM MgCh, 10 mM dNTP, and 10 mM 
DTT were added The mixture was equilibrated to 42°C for 5 minutes. Two hundred 
units of reverse transcriptase was then added and the mixture incubated at 42°C for 50 
minutes. The reaction was terminated by incubating at 70°C for 15 minute. The reaction 
was chilled on ice, collected by brief centrifugation, RNase H was added, and incubated 
at 37°C for 20 minutes. The mixture was stored at -20°C. To amplify the target cDNA, 
the following were combined: 10X PCR buffer, 1.5 mM MgCh, 200 pM each dNTP, 200 
pM gene specific primer [575-1l (Table 5), 575-lL nested primer 1, 5’ GCT AAG AAA 
CTG GGA TAG GA 3’, or 575-1L nested primer 2, 5’CTT CGA TAT TTC TAA AGT 
TGT CTT T 3’], 200 pM abridged universal amplification primer, 2 pi of cDNA 
synthesis reaction, and 5 units Taq DNA polymerase. A layer of sterile mineral oil was 
then added and the reaction collected by brief centrifugation. The reaction was then 
placed in a thermocycler set to the following parameters:
94°C for 3 minutes, then cycled 35 times at 
95°C for 30 seconds
48°C for 30 seconds (575-Il ,575-1l nested primer 1) or 
62°C for 30 seconds (575-Il nested primer 2)
70°C for 2 minutes
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followed by an extended synthesis incubation of 72°C for 3 
minutes.
After the amplification was complete, the sample was analyzed using agarose gel 
electrophoresis and ethidium bromide staining.
Type I DNA Topoisomerase Isolation from C alf Liver
Mitochondrial DNA topoisomerase I was purified from calf liver by the 
procedures listed in appendix I and II (74).
5 ’ and 3 ’ End Labeling o f dsDNA
To phosphorylate the 5’ ends of dsDNA, dsDNA and 10X T4 polynucleotide 
kinase (T4 PNK) buffer were incubated at 70 * C for 1 minute, then quickly cooled on ice. 
Two pi of [y-32P]ATP (3,000 pCi/mmol) and 5 units of T4 PNK were added to the 
mixture, followed by a 30 minute incubation at 37 * C. The reaction was stopped by the 
addition of 2 pi of 0.5 M EDTA. The sample was phenol/chloroform extracted to remove 
protein and ethanol precipated overnight at -20 *C. To radiolabel 3’ ends of dsDNA, 
dsDNA, 10X T4 DNA polymerase buffer, 2 mM dNTPs (N= A, T, or G), T4 DNA 
polymerase, and [a-32P]CTP were mixed, then incubated at 37 *C for 5 minutes. One 
microliter of unlabeled 2 mM dCTP was added to the mixture. The mixture was heated 
at 70 “C for 5 minute. Unincorporated dNTPs were separated by two rounds of ethanol 
precipitation.
Standard Topoisomerase Relaxation Assay
Standard DNA topoisomerase activity was measured by the extent of relaxation of 
supercoiled pUC19 DNA (75). The following components were combined and incubated 
at 37’C for 30 minutes: 10X assay cocktail, pUC19 DNA, topoisomerase, and CIIH2O. 
Topo stop solution was then added, and samples were run at 40 volts for 12 hours on a
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medium sized 0.8% agarose gel. DNA was visualized via ethidium bromide staining. 
One unit of relaxing is equivalent to the amount of activity to relax 50% of plasmid DNA 
within 30 minutes at 37°C.




FIG. 2. Standard mt-topo I relaxation assay. Lane 1, control supercoiled plasmid DNA 
(I); lane 2, rat-topo I at 2 units; lane 3, lunit; lane 4, 0.25 units of activity. The DNA 
bands labeled II, Io, 1r, and I are nicked, linearized, enzymatically relaxed, and 
supercoiled plasmid DNA, respectively.
Cleavage Assay
To determine whether the mt-topo I phosphotyrosine linkage occurs at the 5’ or 3’ 
end of cleaved DNA, a cleavage assay was performed. Topoisomerase was added to the 
following mixture and incubated at 37 #C for 15 minutes: 5’ or 3’ uniquely end labeled 
DNA, 10X assay cocktail, and 25 pM camptothecin unless otherwise noted. The reaction 
was stopped with the addition of SDS (final concentration 0.5%) followed by digestion 
with proteinase K (PK, final concentration 0.5 mg/ml). The sample treated with PK was 
incubated an additional 30 minutes at 55 * C. Alkaline topo stop solution was added to all 
samples. Samples were loaded onto a 2% agarose gel run at 70 volts for 2.5 hours. The
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gel was dried under vacuum and analyzed by autoradiography. Cleavage assay design is 






Z Z ! 3
FIG. 3. Topoisomerase cleavage assay schematic. Doubled stranded fragments of DNA 
that contain known mt-topo I cleavage sites are uniquely end-labeled. The fragments are 
then incubated with mt-topo I in the presence of CPT (which traps the mt-topo I to the 
cleaved DNA). A portion of this reaction mixture is then treated with PK (degrades the 
protein). Samples with and without PK treatment are run on an agarose gel. DNA is 
analyzed via autoradiography. By comparing migration patterns of samples with and 
without PK treatment, the site of mt-topo I binding can be determined. Expected 
migration results are depicted in bottom row of boxes. Lines within boxes represent 
radiolabeled, cleaved DNA fragments with or without the mt-topo I attached.
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fCSDK Precipitation
As schematic of the procedure is depicted in fig. 4. Topoisomerase was added to 
a mixture containing 5’ or 3’ end labeled DNA, 10X assay cocktail, and 25 pM 
camptothecin. The samples were incubated at 37*C for 10 minutes, then divided in half. 
To one half, the DNA was denatured into ssDNA by adding a stop solution containing 
2% SDS, 0.2 M NaOH, 2 mM EDTA and 0.5 mg/ml salmon sperm DNA. In the other 
half, the DNA remained double stranded by adding a stop solution that contained the 
same components as above minus the NaOH. The samples were incubated further, then 
precipitated by the addition of 0.25 M KCI. The samples were spun, the supernatant 
removed, and the pellet washed with a solution containing 10 mM Tris, pH 8.0, 100 mM 
KCI, 1 mM EDTA, and 100 pg/pl salmon sperm DNA solution. After incubation at 
65 °C for 10 minutes, the samples were spun in a microcentrifuge set at maximum speed, 
the supernatant removed, and the pellet resuspended in water. Samples were transferred 
to vials containing scintillation cocktail to be analyzed.
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FIG. 4. Radioactive filter binding/K+SDS‘ precipitation schematic. CPT = camptothecin.
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Drug studies
Drug inhibition studies were performed in the hopes of further distinguishing 
between the mt- and nu-topo I. Quantitative analysis was performed via densitometry 
using Image-1/AT version 4.14 software.
a. Berenil- Berenil is an antitrypanosomal agent that binds to nucleic acid duplexes. 
Berenil (1,3-bis (4’-amidinophenyl)triazene) was added in increments of 10, 40, or 100 
pM to a standard topoisomerase relaxation assay.
b. DMSO- Dimethyl sulfoxide was added in increments of 1%, 5%, or 20% to a standard 
topoisomerase relaxation assay. Previous studies have shown that 5% DMSO inhibits 
mt-topo 160% with no inhibition of nu-topo I (75).
c. Antifungal/antimicrobial agents- Seven antifungal drugs (Al, A6, Bl, Cl, C5, Dl, F2) 
were analyzed at varying concentrations (2X LC50, IX LC50, 0.5X LC50, 0.1X LC50, 
Table 7) in a standard topoisomerase relaxation assay.
TABLE 7
Antifungal/antimicrobial drug LC50s
Drug LC50 (ue/Ml) Microorganism
Al S Micrococcus luteus
Bl 8 Micrococcus luteus
Cl 64 Aspergillus fumigatus
Dl 16 Micrococcus luteus
A6 4 Micrococcus luteus
C5 64 Aspergillus fumigatus
F2 2 Bacillus subtilis,
Myobacterium smeg
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FIG. 5. Structures o f seven antimicrobial/antifungal drugs.




The study began from a mechanistic standpoint to determine the mt-topo I’s site 
of phosphotyrosine linkage at the 5’ or 3’ end of cleaved DNA. Determining the linkage 
site would provide additional evidence to differentiate the nu-topo I from the mt-topo I 
or, in the event of possessing the same linkage site, further characterize the mt-topo I. To 
address the 5’ or 3’ linkage of the mt-topo I, various groups have performed different 
experiments to elucidate this particular aspect of topo I mechanism (44-46). I performed 
the more widely accepted or conventional method, the cleavage assay. By observing gel 
shift patterns of samples treated with and without proteinase K, the cleavage assay 
revealed the mt-topo I linkage site. Another mechanistic study involved the inhibitory 
effect of various drugs on the mt-topo I and nu-topo I. Drug inhibition assays were 
performed in hopes of further delineating the nu-topo I from its mitochondrial 
counterpart, and to compare the sensitivity of topoisomerases isolated from calf liver with 
those isolated from rat liver or calf thymus. Previous studies have reported the mt-topo I 
from rat liver to be sensitive to dimethyl sulfoxide (DMSO) and to the trypanocidal drug 
berenil (75). Drug studies were performed using DMSO and berenil to discriminate 
between the nu-topo I and mt-topo I isolated from calf liver. As well, seven 
antimicrobial/antifungal drugs were assayed to find additional drugs that could 
discriminate between the nu-topo I and mt-topo I.
The molecular component of the study, involved the investigation of genes 
containing topoisomerase domains with the hope of finding the mt-topo I gene. By using 
primers developed from conserved topoisomerase domains in RT-PCR reactions,
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followed by sequencing of the RT-PCR products, and their subsequent characterization 
via similarity searches, an uncharacterized stretch of sequence containing some identity 
to topoisomerases was found. The sequence, designated 575-1, was used as a probe to 
screen a human cDNA library, as a probe in a northern blot, and as a gene specific primer 
in 3’ rapid amplification of cDNA ends (RACE) reactions.
In addition, to further characterize 575-1 and the other RT-PCR products 
generated from topo conserved domains, an evolutionary molecular analysis against 
seven known eukaryote type I topoisomerase genes was performed. Multilevel consensus 
sequence analysis (MEME), and phytogeny tree (dnapars) bioinformatics programs were 
performed to show what relationships, if any, exist between known eukaryotic type I 
topoisomerases and RT-PCR products generated from a eukaryotic topo I primer set, C- 
D. The C-D primer set was of particular interest, due to the fact that they flank the type I 
topoisomerase catalytic domain.
MECHANISTIC ANALYSIS
Purification o f the Mitochondrial Type I  DNA Topoisomerase
The mitochondrial DNA topoisomerase I has been shown to be a 78 kDa protein 
(p78) (75). As described in the methods section, starting with 1 kg of calf liver, mt-topo I 
activity was tracked after each column purification by means of a standard topoisomerase 
relaxation assay. Protein concentrations were determined by Bradford analysis. Fig. 6 
shows column fractions displaying topo activity. Fractions showing topo activity were 
combined and loaded onto the next column. Total topoisomerase activity detected for 
each column fraction is shown in Table 8. Evidence of topo activity was seen as a ladder
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of bands which represented varying levels of plasmid relaxation. In the phosphocellulose 
column a faint ladder was seen in fractions 60 through 93. Ideally, topoisomerase 
activity should be captured over a much smaller range, but due to the fact that the 
phosphocellulose bed volume was too large in comparison to the amount of protein 
loaded, the protein came off the column at a much slower rate. These fractions were 
combined and loaded onto a hydroxyapatite column. In the hydroxyapatite column, 
fractions 41 through 57 were collected and loaded onto the dsDNA cellulose column. 
The topoisomerase activity appeared to peak at fraction 45 and then decrease with each 
subsequent fraction. In the dsDNA cellulose column, fractions 7 and 8 were combined 
and applied to a centricon-10 concentrator. The purified mt-topo I had a short half-life 
with topoisomerase activity decreasing over a period of a few weeks. Previously isolated 














Crude 490 18914 38.6 ND
Mitochondria
Pure 240 468 1.95 ND
Mitochondria
S2 40 ND ND 169,200
PC 225 ND ND 52,500
HA 80 ND ND 48,000
dsDNA cellulose 4.1 ND ND 3.075
Note. S2 (supernatant 2), PC (phosphocellulose column), HA (hydroxyapatite column), 
ND (not determined, protein concentration below level of detection by Bradford analysis)
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
43
fraction 60 63 66 69 72 75 78 81 84 87 90 93 97 100
dsDNA CELLULOSE COLUMN 
FIG. 6. Active topo I fractions from calf liver. pUC19 alone (control).
Cleavage Assay
A distinguishing feature of type IB eukaryotic topoisomerases is that they become 
linked to the 3’ terminus of a cleaved DNA strand (16), while the type IA bacterial 
topoisomerases become linked to the 5 ’ terminus of the broken strand (76). One method 
of determining the linkage site is by observing whether the topoisomerase becomes 
radiolabeled when using uniquely end-labeled substrates. This is often assessed by the 
following three experiments.
PHOSPHOCELLULOSE COLUMN
Control 39 41 43 45 47 49 51 53 55 57
HYDROXYAPATITE COLUMN
Control 6 7 8
}Ib
n+io
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The results of two different experiments suggested that the mitochondrial 
topoisomerase is linked to the 5’ terminus via a phosphotyrosine linkage. The first 
experiment involved the use of uniquely end-labeled substrates, which were assessed by 
measuring radioactivity after filter binding (77) or potassium sodium dodecyl sulfate 
precipitation (SDS) (figure 4, schematic diagram) (78). Radioactive filter binding 
involved spotting a reaction mixture of end-labeled DNA incubated with and without 
topoisomerase. The filters bound high molecular weight (MW) molecules such as DNA 
linked to topoisomerase. Subsequent washings of the filters removed lower MW 
molecules. If the DNA were 3’ labeled, for example, and the topoisomerase was 5’ 
linked, a high amount of radioactivity would be detected on the filter. Analogously, if the 
DNA were 5’-end labeled, and the topo was 5’ linked, low amounts of radioactivity 
would be detected. Low levels of radioactivity would result because the topoisomerase 
would be bound to the unlabeled portion of the DNA cleavage product, and therefore, be 
undetected by the counter. The potassium-SDS precipitation method, on the other hand, 
worked along similar lines, except that instead of using filters, SDS bound the topo while 
it was still linked to the radiolabeled DNA. This SDS/topo/DNA complex was then 
precipitated and counted. End-labeled DNA with no topoisomerase attached to it would 
be detected with little or no counts because the radiolabeled DNA cannot bind to the SDS 
alone.
My own radioactive filter binding experiments did not provide reliable results. 
The inconsistency in data was believed to be due to the observed high background levels. 
I was also unable to obtain expected results for a positive control. Nu-topo I was used to 
serve as a 3’ end linkage positive control. Using a 3’ end labeled substrate, low counts
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were expected when nu-topo I was used in this assay. For both ssDNA and dsDNA 
substrates (sample 6-9, table 9) higher then expected counts, relative to the background 
reading (sample 5, table 9), were seen. Background levels were determined by spotting a 
mixture consisting of all assay components minus the topoisomerase onto DE-81 disks. 
High background counts, as shown in sample 5 of table 9, indicated that the radiolabeled 
substrate was somehow interacting with K+SDS‘ without the presence of the 
topoisomerase to link it. BSA contained in the 10X assay cocktail and/or the presence of 
too high a concentration of K+SDS" was thought to contribute to the high background 
readings. The procedure was therefore repeated using in assay cocktail that did not 
contain BSA and decreased amounts of fC+SDS*. The hope was that by reducing the 
background more consistent readings would be obtained.
TABLE 9
K+SDS' Precipitation Assay Using 3’ End-labeled H-ori as the Substrate 











1 1 6332 3318
2 2.5 — 8995 7912
3 5 — 7130 5320
4 10 — 8402 7197
5 0 0 5199 4034
6 — 1 5734 4703
7 — 2.5 7120 5170
8 — 5 9118 5184
9 — 10 6885 5840
The next K+SDS' precipitation assay attempt, as previously mentioned, focused 
on reducing the background counts. Three samples were prepared. The first tested
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whether BSA contributed to high background counts by eliminating it from the assay 
cocktail. The second tested whether the [SDS] in the stop solution was high by reducing 
it from 2% to 1.5%. The last sample tested for both variables by containing no BSA and 
1.5% SDS. As seen in table 10, the overall background was reduced as compared to the 
first background reading (sample 5, table 9). The ssDNA sample 2 had a 11% lower 
background then sample 1, and a 3.6% lower background then sample 3. The 11% 
decrease in background may be due to the fact that there was simply more SDS available 
to interact with the radiolabeled substrate. The dsDNA sample 2 was 88% lower then 
sample 1, and 41% lower then sample 3. The 88% difference observed in sample 2 may 
be due the fact that less than 1.5% SDS was added to this particular sample due to 
pipetting error. After spinning the samples down, I observed a smaller pellet in sample 2 
as compared to the other samples. However, in both ssDNA and dsDNA samples, where 
no BSA was present and SDS amounts were reduced, there was an overall decrease in 
background. The assay was therefore repeated using these modifications.
TABLE 10
K+SDS* Precipitation Assay Background Check




The third K+SDS* precipitation assay attempt using no BSA and 1.5% SDS was 
performed in duplicate. Once again, inconsistent data was observed. Background levels 
continued to be high with an average value o f4562 cpm between the two sets of assays.
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Trends observed in one set; for example, increase in counts with increase in amount of 
topoisomerase added, were not seen in the corresponding duplicate set. Therefore, the 
K+SDS' precipitation assay was abandoned.
As an alternative approach, the exonuclease ID method performed by Jessica Lin 
proved to be more reliable (92). Exonuclease m  (Exo EH) is a 3’->5’ exonuclease that 
produces 5’ mononucleotides, and is specific for double-stranded DNA that has a free 3’ 
hydroxyl terminus at blunt or 5’ overhanging ends or at a nick (75). If the 3’ end of the 
DNA break is free of enzyme attachment, the Exo III will degrade the DNA strand. This 
decrease in size of the topo-Exo III products would increase the migration rate upon gel 
electrophoresis compared to topo cleavage products not treated with Exo III. If the 3’ 
end of the DNA break is blocked by enzyme, no change in the migration pattern of topo 
cleavage products would occur upon Exo III treatment The results of the cleavage assay 
after treatment with Exo III showed that the migration rates of the nu-topo I products 
seem to be unaffected by treatment with Exo HI. This is expected since it has been 
established that the nu-topo I becomes linked to the 3’ terminus of cleaved DNA (16). In 
the case of the mt-topo I, the Exo III treatment increased the migration rate, reflecting a 
decrease in size of mt-topo cleavage products. The data from this experiment suggested 
that mt-topo I is linked at the 5’ end of the cleavage site, leaving a free 3’ hydroxyl group 
on the other side of the break which would serve as a substrate for Exo HI.
Two additional assays used to support the 5’ end linkage results are variations of 
the topoisomerase/Exo HI assay. The results from these studies indicated a blocked 5’ 
terminus and a free 3’ hydroxyl group being generated by the mitochondrial enzyme (74). 
The suggestion from these three independent, less conventional methods was that the mt-
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topo I was covalently linked through a phosphotyrosine to the 5’ end of the cleaved 
DNA.
To determine the mt-topo I using the more widely accepted method, I performed 
cleavage assays using 3’ end or 5’ end labeled H-ori (mitochondrial heavy strand 
replication origin, 797 bp) or TERM (mitochondrial terminator region, 387 bp). H-ori 
and TERM DNA fragments were used as substrates because they contained known 
preferential mt-topo I cleavage sites (74). These fragments were PCR amplified from 
recombinants that contained H-ori or TERM inserts (fig. 7).
Lane 1 2  1 2
A B
FIG. 7. PCR amplified H-ori and TERM DNA fragments. Lane 1, A and B, 100 bp MW 
ladder, lane 2, A, H-ori; lane 2, B, TERM.
H-ori and TERM were then 3’ or S’ end labeled using two different techniques. 
To produce uniquely 3’ end labeled substrates, T4 DNA polymerase and [a-32P] dCTP 
were used to replace a unique C at the 3’ end of the H-ori or TERM DNA fragment (fig. 
8). To produce uniquely 5’ end labeled substrates, T4 polynucleotide kinase and [Y-32P] 
ATP were used. This reaction was then followed by a Hinf I digestion, which 
specifically cleaves one of the two radiolabeled S’ ends generated from the T4 PNK
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reaction (fig. 9). H-ori and TERM possess unique Hinf I restriction enzyme sites near 















FIG. 8. Autoradiograph of 3’ end labeled TERM. Underlined cytosine is removed and 





FIG. 9. Autoradiograph o f 5’ end labeled H-ori. Lane 1, undigested 5’ end labeled H-ori; 
lane 2, Hinf I digested 5’ end labeled H-ori.
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Before performing the cleavage assay, a serial dilution of the mt-topo I was tested 
in order to determine the optimal units of activity needed to perform the cleavage assay. 
Both 5’ and 3’ end labeled substrates were tested. Fig. 10 shows the results of a mt-topo 
I dilution using 5’ end labeled H-ori. At 100 units of mt-topo I activity the DNA is 
digested away, at 50 units a few cleavage products are evident, and at 25 units products 
are evident but with slightly less intensity. For 5’ end labeled H-ori, 50 units of mt-topo 
I activity was determined to be the optimal amount of activity for use in the cleavage 
assay.
Lane 1 2 3
FIG 10. Mt-topo I serial dilution using 5’ end labeled H-ori. Lane 1, 100 units mt-topo 
1/25 pM CPT; lane 2, 50 units mt-topo 1/25 pM CPT; lane 3, 25 units mt-topo 1/25 pM 
CPT. Arrows indicate cleavage products.
Fig. 11 shows the results o f a mt-topo I dilution using 3’ end labeled term. At 100 
units of mt-topo I activity some cleavage products are visible, at 50 units cleavage 
products were completely digested, and at 25 units more concentrated cleavage products
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are evident. For 3’ end labeled term, 25 units of mt-topo I activity was determined to be 
the optimal amount of activity for use in the cleavage assay. It is unknown as to why 
products were digested away at 50 and not 100 units of topo activity. The inability to 
cleave was attributed to low stock concentrations of active mt-topo I.
Lane 1 2 3
FIG. 11. Mt-topo I serial dilution using 3’ end labeled TERM. Lane 1, 100 units mt-topo 
1/25 pM CPT; lane 2, 50 units mt-topo 1/25 pM CPT; lane 3, 25 units mt-topo 1/25 pM 
CPT. Arrows indicate cleavage products.
Cleavage assay attempts using 5’ end labeled DNA were unsuccessful. No 
cleavage products were evident using 50, 75, or 100 units of mt-topo I activity. The 
inability to cleave was attributed to low mt-topo I stock concentrations.
Cleavage assay attempts using 3’ end labeled H-ori showed the mt-topo cleavage 
products aggregating together, unable to enter the agarose gel in the absence of PK (fig. 
12, lane 5). Addition of PK resulted in migration of numerous cleavage products into the 
gel (lane 6). When the topoisomerase is removed from the 5’ end by digestion with 
proteinase K, cleavage products were free to migrate. This shows that the topoisomerase
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is linked to the 5’ end of the cleaved DNA. This agrees with the data from the 
exonuclease HI assay result The presence of the enzyme on the 5’ end of DNA is 
catenating or holding broken strands together causing them to form one large structure 
which could not pass through the agarose gel.
The overall difficulty in obtaining cleavage products for 5’ end labeled substrates 
was attributed to the low stock concentration of the mt-topo I. As cleavage assay 
experiments were performed, the enzyme, possibly due to repeated exposure to freezing 
and thawing, lost more then half of its activity over a few months. Therefore, to maintain 
the levels of mt-topo I activity needed, I increased the volume of enzyme added to the 
cleavage assay reaction mixture. Originally, the mt-topo I was assayed at 10 units/pl. 
After a few months, the activity was assayed at 4 units/pl. Instead of adding 5 pi to a 30 
pi total volume to obtain 50 units of activity, I had to more then double the volume. This 
large increase in enzyme volume may have altered the cleavage assay cocktail final 
concentrations; therefore, contributing to the inability of the mt-topo I to properly cleave. 
Two attempts were made to isolate fresh mt-topo I from calf liver to use in the cleavage 
assay. As previously described, the isolated mt-topo I had a short half-life. 
Topoisomerase used in these assays were from previous calf liver preparations (74).
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Lane 1 2 3 4 5 6
FIG. 12. 3’ end labeled cleavage assay. Lane 1,3’ end 32P labeled H-ori alone; lane 2 ,3’ 
H-ori and CPT; lane 3, 3’ H-ori and PK; lane 4, 3’ H-ori and SDS; lane 5, 3’ H- 
ori/CPT/SDS and mt-topo I; lane 6, 3’ H-ori/CPT/SDS/mt-topo I and PK. Arrows 
indicate released cleavage products.
Drug Inhibition Assay
Drug inhibition assays were performed in hopes of further delineating the nu-topo 
I from its mitochondrial counterpart, and to compare the sensitivity of topoisomerases 
isolated from calf liver with those isolated from rat liver or calf thymus. The enzymes 
were serially diluted and topo activity determined by a standard topoisomerase relaxation 
assay. The same serially diluted set o f  enzymes were used in subsequent mixtures
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containing the drug of interest at varying concentrations. By comparing topoisomerase 
activity with and without the drug, differences in activity could be observed.
Five percent DMSO had previously been shown to inhibit mt-topo I activity 
isolated from calf thymus by 60% and result in almost total loss of activity with addition 
of 20% DMSO. Calf thymus nu-topo I was found to be uninhibited by 5% DMSO, but 
at a higher concentration of 20% DMSO, -50% inhibition was observed (75). In my 
DMSO inhibition studies, I added DMSO to final concentrations of 1%, 5%, and 20% in 
standard topoisomerase relaxation assays using a serial dilution of mt-topo I or nu-topo I 
isolated from calf liver.
In assaying the nu-topo I, there appeared to be an average value of 3.7% 
inhibition using 1% DMSO (see Graph 1, fig. 13, and Table II, lane 5-7 compared with 
lanes 2-4, percentages are based on densitometry results from photographs of agarose 
gels). Using 5% DMSO, there appeared to be increases in nu-topo I activity in lane 8 
(1.9 units topo activity, 16% increase), and in lane 9 (2.0 units of topo activity, 5% 
increase). A slight decrease in activity (5.9% inhibition) was observed in lane 10. This 
apparent stimulation of activity by 5% DMSO has been observed in a previous study 
(75). As depicted in lanes 11-13 (fig. 13), nu-topo I activity was inhibited by an average 
value of 28% with addition of 20% DMSO.
The nu-topo I did not completely correlate with previous studies. The calf liver 
nu-topo I was inhibited 28% as compared to 50 % inhibition in the presence of 20% 
DMSO, and showing a slight inhibition verses no inhibition in the presence of 1% 
DMSO. But, as in the previous study, the nu-topo I displayed some stimulation of 
activity in the presence of 5% DMSO.
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DMSO Percent Inhibition 
Densitometry results for figures 16 and 17, respectively.








1 0 0 0
2 1.6 0 0
3 1.9 0 0
4 1.7 0 0
5 1.6 0 1
6 1.8 5.3 1
7 1.6 5.9 (5.7) 1
8 1.9 0 5
9 2.0 0 5
10 1.6 5.9(2) 5
11 1.3 19 20
12 1.7 11 20
13 0.75 53 (28) 20








1 0 0 0
2 2 0 0
3 1.9 0 0
4 1.5 0 0
5 1.9 5 1
6 1.2 37 1
7 1.2 20(21) 1
8 1.7 15 5
9 1.2 37 5
10 0.98 35 (29) 5
11 0.83 58 20
12 0.24 87 20
13 0.34 77(74) 20
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Lane 1 2  3 4 5 6 7 8 9 10 11 12 13




FIG. 13. DMSO inhibition assay of nu-topo I. Lane 1, pUC19 alone; lane 2, -2  units nu- 
topo I; lane 3, ~1 unit nu-topo I; lane 4, -0.5 units nu-topo I; lane 5, -2  units nu-topo 
1/1% DMSO; lane 6, -1 unit nu-topo 1/1% DMSO; lane 7, -0.5 units nu-topo 1/1% 
DMSO; lane 8, -2  units nu-topo I/5%DMSO; lane 9, -1 unit nu-topo 1/5% DMSO; lane 
10, -0.5 unit nu-topo I/5%DMSO; lane 11, -2  units nu-topo V 20% DMSO; lane 12, -1 
unit nu-topo 1/20% DMSO; lane 13, -0.5 units nu-topo 1/20% DMSO.
Lane 1 2 3 4 5 6 7 8 9 10 11 12 13
■Q m■SI ■HH mM 11 UH
FIG. 14. DMSO inhibition assay with mt-topo L Lane I, pUC19 alone; lane 2, -2  units 
mt-topo I; lane 3, -1.75 unit mt-topo I; lane 4, 1 units mt-topo I; lane 5, -2  units mt-topo 
1/1% DMSO; lane 6, -1.75 unit mt-topo 1/1% DMSO; lane 7, -1 units mt-topo 1/1% 
DMSO; lane 8, -2  units mt-topo I/5%DMSO; lane 9, -1.75 unit mt-topo 1/5% DMSO; 
lane 10, -1 unit mt-topo I/5%DMSO; lane 11, -2  units mt-topo V 20% DMSO; lane 12, 
-1.75 unit mt-topo 1/20% DMSO; lane 13, -1 units mt-topo 1/20% DMSO.
The calf liver mt-topo L on the other hand, was inhibited by an average value of 
21% in the presence of 1% DMSO (Graph 1, fig. 14 and Table 11, lanes 5-7) and an 
average value of 29% inhibition in the presence of 5% DMSO (lanes 8-10). 29% 
inhibition did not correlate with previous reports of 60% inhibition. Mt-topo I activity, as
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in previous studies, was highly inhibited by 20% DMSO possessing an average value of 
74% inhibition (lane 11-13).
Less inhibition was observed than expected for the mt-topo I in the presence of 
5% DMSO, 29% verses 60 % inhibition. In the presence of 20% DMSO, mt-topo I did 
correlate with previous results, displaying high levels of inhibition.
The overall conclusion was that the mt-topo I was more sensitive to inhibition by 
DMSO than its nuclear counterpart DMSO may be used to distinguish calf liver mt-topo 
I from calf liver nu-topo I. In addition, each enzyme followed the overall trends of the 
previous study. The slight differences seen in my experiments may be attributed to minor 
structural differences between enzymes isolated from calf liver verses rat liver.
DMSO Inhibition A ssay
a i S .  20%
■ nu-topo I
■ mt-topo I
0% 1% 5% 20%
Percent DMSO
GRAPH 1. DMSO inhibition of nu-topo I and mt-topo I 
(nu-topo I is represented by the left bar, mt-topo I by right bar)
In the case of the trypanocidal drug, berenil, previous reports have found that, like 
DMSO, berenil can differentiate between the mt-topo I and nu-topo I. Calf thymus nu- 
topo I was found to be unaffected by 5-50 pM berenil. While calf thymus mt-topo I was 
inhibited 37% in the presence o f 5 pM berenil and inhibited 63% by 20 pM berenil (75). 
In order to observe various levels of berenil inhibition with mt-topo I and nu-topo I,
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samples purified from calf liver, 10,40, and 100 pM final concentrations of berenil were 
added to standard topoisomerase relaxation assays. Fig. 15 shows the berenil assay results 
for mt-topo I (lanes 2-9) and nu-topo I (lanes 10-17). By comparing the same levels of 
mt-topo activity without berenil (lane 2,3) verses with 10 pM berenil (lane 4,5), an 
average value of 5% inhibition of relaxation activity was observed. Inhibition of mt-topo 
activity increased to 23% when 40 pM berenil was added (lane 6,7). Twenty-eight 
percent inhibition was observed with the addition of 100 pM berenil (lane 8, 9). As 
compared to previous studies with calf thymus mt-topo I, much less inhibition was 
observed for calf liver mt-topo I. The nu-topo I, exhibited some inhibition in the 
presence of berenil. Average inhibition values of 11% in the presence of 10 pM berenil, 
16.5% in the presence of 40pM berenil, and 11% in the presence of 100 pM berenil were 
detected (lanes 10-17). Calf liver nu-topo I, in contrast to calf thymus nu-topo I, was 
slightly inhibited by berenil. Calf liver nu-topo I was inhibited less than calf liver mt- 
topo I in the 40-100 pM berenil range.




FIG. 15. Berenil assay. Lane 1, pUC19 alone; lane 2, ~2 units mt-topo; lane 3, ~2 units
mt-topo; lane 4, ~2 units mt-topo/lOpM berenil; lane 5, ~2 units mt-topo/lOpM berenil;
lane 6, -2  units mt-topo/40pM berenil; lane 7, -2  units mt-topo/40pM berenil; lane 8, ~2 
units mt-topo/lOOpM berenil; lane 9, ~2 units mt-topo/100pM berenil; lane 10,1 unit nu- 
topo; lane 11, 0.5 unit nu-topo; lane 12, I unit nu-topo/lOpM berenil; lane 13, 0.5 unit 
nu-topo/lOpM berenil; lane 14, 1 unit nu-topo/40pM berenil; lane 15, 0.5 unit nu- 
topo/40pM berenil; lane 16, 1 unit nu-topo/lOOpM berenil; lane 17, 0.5 unit nu- 
topo/lOOpM berenil.
n  H  «  N  H  H  *'  M
- I  ■ ■
’ I 1 .
*»
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TABLE 12
Berenil Percent Inhibition 
Densitometry results for figure 18. Mt-topo activity shown in lanes 2-9, nu-topo I 
activity shown in lanes 10-17. Average value written in parentheses.






1 0 0 0
2 2 0 0
3 1.9 0(0) 0
4 1.8 10 10
5 1.9 0(5) 10
6 1.5 25 40
7 1.5 21 (23) 40
8 1.4 30 100
9 1.4 26 (28) 100
10 1.8 0 0
11 0.8 0(0) 0
12 1.4 22 10
13 1.4 0(11) 10
14 1.2 33 40
15 0.95 0(16.5) 40
16 1.4 22 100
17 1.8 0(11) 100
In the antimicrobial/antifungal inhibition studies, six (Al, A6, Bl, C5, Dl, F2) of 
the seven drugs did not inhibit the mt- or the nu-topos. The mt-topo I was not inhibited 
by the drug Cl, but the nu-topo I was inhibited in a dose-dependent fashion. At a 
concentration of 2X LC50 (46 pM), Cl inhibited nu-topo I activity by %60. Fig. 16 and 
Graph 2 shows a decrease in topoisomerase activity with increased addition of Cl. The 
nu-topo I was found to be more sensitive to inhibition by Cl than its mitochondrial 
counterpart
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Lane 1 2  3 4 5
FIG. 16. Nu-topo I Cl inhibition assay. Lane 1, nu-topo I alone; lane 2, nu-topo I and 










GRAPH 2. Effects of Cl on the mt-topo I and nu-topo I 
(bars from left to write correspond with labels in box starting from the top)
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MOLECULAR ANALYSIS
Human Placental Tissue Isolation
To prepare a probe to screen a cDNA library for the mt-topo I gene, RT-PCR was 
performed on total RNA isolated from human placenta. From a 600 mg sample of human 
placental tissue, 93 pg of total RNA were recovered. A 260:280 ratio of 1.88 indicated 
minimal protein contamination of the RNA sample. Formaldehyde gels revealed intact 
28S and 18S rRNA bands with minimal degradation (fig. 17).
28S rRNA
18S rRNA
FIG. 17. Total RNA isolation from human placental tissue. Lane 1, total human placental 
RNA samples (2 pg); lane2, RNA MW Markers (3pg).
RT-PCR
DNA was successfully synthesized from RNA using primers homologous to 
conserved regions in eukaryote and prokaryote type I topoisomerases (fig. 18 and 19). A 
through D represent the four conserved eukaryotic type I topoisomerase domains. 
Products produced using region D were of particular interest due to the fact that D
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contains the topoisomerase catalytic domain. Figure 18 shows the expected size 
fragments that are generated from the known human nu-topo I. A 1590 bp nu-topo IPCR 
product would be generated using the primer set Al and Drev. A 1090 bp nu-topo I PCR 
product would be generated using the primer set Al and C ^. A 531 bp nu-topo I PCR 
product would be generated using the primer set Cl and Drev. Figure 20 shows the 
expected size fragment for the known bacterial topo I, using Apr0L and CproR. Degenerate 
conserved type I topoisomerase primers from five different eukaryotic species were used 
with the idea that messages that contained type I topoisomerase conserved domains 
would be amplified. Several RT-PCR products were purified, sequenced, and subjected 
to a Genbank search for identification. The hope was to find a stretch of sequence that 
was uncharacterized yet possessed some prokaryotic and /or eukaryotic topoisomerase 
identity.






—  531 bp
FIG. 18. Primers and expected RT-PCR DNA products of eukaryotic primers. Sizes seen 
on right represent expected size fragments for the known human nu-topo L
A
A
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A B C D consensusprokaryotic
sequence
A C 517 bp
FIG. 19. Primers and expected RT-PCR DNA products of prokaryotic primers. Sizes 
seen on right represent expected size fragments for the known Zs. Coli topA.
As a positive control for RT-PCR, an expected 300 bp region of a-actin was 
amplified. The primers were provided by Dr. William Kearns of the Center for Pediatric 
Research at Eastern Virginia Medical School. Fig. 20 shows the results of PCR 
amplification of actin. The expected 300 bp product is seen in lane 2.
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Lane 2
~ 7 0 0 b p _ *  
-575 b p  ^ 500 bp
FIG. 21. RT-PCR using degenerate C-D primer set Lane 1, Degenerate C l-D r RT-PCR 
products; lane 2,100 bp MW marker.
One RT-PCR product of particular interest, 575-1, was generated using the 
degenerate Cl-Drcv primer set (fig. 18,21). The two products seen in fig. 21, in addition 
to other RT-PCR products generated from different conserved topo primer sets, were 
purified (fig. 22). Purified RT-PCR products were cloned into pGEM vectors, 
sequenced, and then characterized via similarity searches. Out o f 6 colonies selected and 
grown from the purified degenerate C-D 575 ligation mixture, the sequence of the clone 
from the first colony, called 575-1, when subjected to computer generated similarity 
searches was found to possess both topo I and topo II signature similarity. Sequence 
information obtained of the clone from the sixth colony, designated 575-6, was found to 
be the known human nu-topo I. Finding the known nu-topo I served as a more specific 
positive control by confirming that the use of the degenerate type I topoisomerase 
conserved primer sets in RT-PCR reactions can generate a topoisomerase gene. The RT- 
PCR product sequenced and their corresponding similarity search results are displayed in 
Tables 8-16.
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Lane 2 3 4 5 6
500 bp ^
+— 700 bp 
4 400 bp
FIG. 22. Purified RT-PCR products. Lane 1, 100 bp MW ladder, lane 2, Deg A l-C r 425 
bp; lane 3, Pro A l-Cr 450 bp; lane 4, Pro A l-C r 400 bp; lane 5, Deg Cl-Dr 700 bp; lane 
6, Deg C l-D r 575 bp.
Since it was unknown how related the mt-topo I gene was to the known nuclear 
topo, each RT-PCR was initially conducted under less stringent conditions, ie. low 
annealing temperature and varying Mg2+ concentrations. After obtaining several 
products from one primer set, the stringency was gradually increased in order to decrease 
the production of products generated from nonspecific binding. Fig. 23 shows an 
optimization of RT-PCR product synthesis by modifying the MgCh concentration and 
annealing temperature. Each RT-PCR product in lane 4 was subsequently cut from an 
agarose gel, purified, and sequenced. Not all fragments were sequenced due to 
difficulties inherent in using degenerate primers. These difficulties are discussed in 
greater detail in the sequencing results section.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
66
Lane 1 2  3 4
500 bp
FIG. 23. Optimized RT-PCR product synthesis. Lane 1, 100 bp MW Marker, lane 2, Pro 
Al-Cr 3 mM MgCh; lane 3, Pro Al-Cr 4 mM MgCfe; lane 4, Pro Al-Cr 4 mM MgCb + 
increase in annealing T by 1°C.
Plaque PCR
This procedure was developed in order to provide a fast and easy way to screen 
potential cDNA positives. Plaques, that were cored out with pasteur pipet tips and 
resuspended in SM buffer, served as template sources in standard PCR reactions.
Since 575-1 was uncharacterized, yet possessed some topoisomerase similarity it 
was used as a probe to screen a human cDNA library. Plaque PCR was used to determine 
if tertiary cDNA screen positives did, in fact, contain a portion of the 575-1 probe. A 
575-1 internal primer set was developed using PCR Primer Design software to amplify an 
expected 274 bp region (results, fig. 24; diagram, fig. 29). Clone 6A was the only 
sample to produce the expected fragment.
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Lane 1 2 3 4 5 6 7 8
500 bp
FIG. 24. Plaque PCR using 575-1 internal primers. Lane 1, 100 bp MW marker, lane 2, 
positive control; lane 3, putative 3° positive 3A; lane 4, 6A; lane 5, 7B; lane 6, 10A; lane 
7, 11A; lane 8, 12A.
Plaque PCR was also performed to quickly screen potential topo II cDNA 
positives. A mixture of five topo II probes developed from conserved type II 
topoisomerase regions were used to screen a human cDNA library. To eliminate 
extraneous DNA bands that were due to amplification of the bacterial vector, a 
“negative” plaque was amplified along with positives (fig. 25, lanes 6-8). For example, 
by comparing bands seen in lane 6 (negative control) against PCR products generated 
using the same primer sets, as in lanes 2 and 5, irrelevant products can be eliminated.
As shown in fig. 25, several PCR products were generated using 3 different topo 
II primer sets. Clone 10-2 produced products for all three primer sets, making it a 
potential mt-topo II candidate. An expected size nu-topo II fragment was seen for the 5’ 
primer set (-517 bp) in addition to many other products for clones 10-2 and 19-1A (lane 
2 and 5). Clones 10-2 and 19-1A lost their viability after a few weeks, ie. would not 
grow, before sequence information o f the inserts could be obtained. Attempts were made 
to sequence plaque PCR products. A 400 bp plaque PCR product generated using topo II 
5’LR primer set was sequenced (Table 14).
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FIG. 25. Plaque PCR products using topo II primers. Lane I, 100 bp MW Markers; lane 
2, plaque 10-2 topo II 5’LR primers; lane 3, plaque 10-2 topo II mid LR primers; lane 4, 
plaque 10-2 topo II 3’ LR primers; lane 5, plaque 19-1A 5’ LR primers; lane 6, negative 
control topo II 5’LR primers; lane 7, negative control topo II mid LR primers; lane 8, 
negative control topo II 3’LR primers.
pGEM Vector Cloning
RT-PCR products of interest were inserted into pGEM vectors to facilitate cycle 
sequencing. Inserts were flanked by SP6 and T7 polymerase promoters, and therefore, 
could be amplified and directly sequenced using primers representing either promoter 
sequence. The pGEM vector’s multiple cloning region was within the coding region of 3- 
galactosidase. Insertional inactivation of 3-galactosidase allowed recombinants to be 
directly identified by blue/white screening. Successful insert ligation was indicated by a 
white bacterial colony. A blue colony indicated unincorporation of the insert Rapid 
plasmid preparations were performed with samples run on agarose gels to confirm 
successful ligation of insert ssDNA isolations were also performed in an effort to 
provide a purer template source for cycle sequencing.
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Rapid Plasmid Preparation
Fig. 26 shows a 1% agarose gel of double stranded DNA isolated from individual 
clones recovered after plating PCR insert/pGEM vector cloning reactions. As expected, 
slower migrating bands were seen for recombinants that contain inserts (lanes 1,3) and a 
faster migrating band for the vector alone (lane 2).
Lane 1 2 3
FIG. 26. Rapid plasmid preparation. Lane 1, Deg. C-D 290 bp insert white colony; lane 
2, no insert blue colony; lane 3, Deg. A-C 900 bp insert white colony.
ssDNA Isolation
Fig. 27 shows a 1% agarose gel of single stranded DNA isolated from pGEM 
vectors with 575-1 and 575-6 inserts.
Lane 1 2
ssDNA
FIG. 27. ssDNA isolation. Lane 1, degenerate conserved topo primer set C-D 575-1; lane 
2, degenerate conserved topo primer set C-D 575-6. Faint upper band is the helper phage
DNA.
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Cycle Sequencing
Initially, RT-PCR products were commercially sequenced. The sequencing lab 
successfully sequenced only 2 out of the 8 samples sent. The low success rate was 
attributed to the unpredictable nature of working with degenerate oligomers. In lab 
sequencing was more productive because it allowed for the optimization of parameters 
needed in order to obtain legible sequence. Higher concentrations of degenerate primers 
were needed in order to obtain the appropriate concentration for the one primer in the 
degenerate set that was specific to the RT-PCR product of interest Sequencing of 
products produced from degenerate primers was further complicated by the fact that 
contamination of a comigrating product was common. Insertion of the RT-PCR product 
into a vector eliminated the problem of comigrating products due to the fact that only one 
product can be inserted into the vector. Cycle sequencing using these cloned 
recombinants as templates provided more legible sequence.
Fig. 28 shows a cycle sequencing diagram for a commercially sequenced RT-PCR 
product of ~l 100 bp. Having ligated purified RT-PCR products into a pGEM vector, the 
inserts were sequenced with SP6/T7 primers. SP6 and T7 promoters flank the pGEM 
insertion site. Since these primers annealed to regions just outside of the insert, they 
eliminated sequencing problems due to degenerate primer use. Several RT-PCR products 
were sequenced. Tables 13-15 show the primer sets used, product sizes, and sequences 
obtained.
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V / k i &
FIG. 28. Cycle sequencing diagram of 1100 bp Deg A l-C r  RT-PCR product Four 
different color waves are used to represent G, A, T, or C.
575-1 nested primer 2 
for 3’ RACE
575-1 nested primer 1 
for 3’ RACE
575-1 r 575-1r
61 176 277 321 335
575-1 internal forward 
sequencing primer
Expected 274 bp PCR 
product for screening 
potential positive cDNA 
clones
410 -575 bp
Total bps sequenced using 
pGEM T7 forward and 
575-1 internal forward 
primers
FIG. 29. Diagram of 575-1 primers. Primers generated from known sequence 
information obtained for 575-1. The primers 575-U and 575-lR were used in plaque 
PCR reactions to screen potential cDNA positive clones. 575-1 internal forward primer 
was developed as an internal sequencing primer. Nested primer 2 and nested primer 1 
were used in 3’RACE reactions.

















Deg C l-D r  
(reverse)
Deg C l-D r  
(reverse)



















GCCCTCGAATTGGCT AAAGTGAG AAACT GGGCTG AAG ACTC
CGTACCCTCTGCCATCTTGCCGAGGGAGTCTCTTTAGAAACA
TCAAGGTATTCGATGGTCGATGATCC ATT AG
ATGGAC AC AAGGAGGC AAAATT CTAAAT GTGAC C ACT GGGT
CTTGGGAATCAGTAGGGGCTGTATCCAGCACACCACTGCCC
AGTTAATCTACTTGCTG AACTC AGGAAATT CCTATCACTGAC 
CCTGGCCAGGGCTTTAAAGGGTAGGAAAGCATTAATGCATC 
TTA TGG AAC ACA GCA GCC TAA ATA CAG AGA GAA AAT 
AGA GTG CAG ACT GTA GCT TTC TTT GTG CTGT CAG TAT 
TAT TTA ATT TAT GTT ACA TTA CAT TAC A
ATGGAGAACAAGCAGCCCGAGGATGATCTTTTTTGATAGAC





TAT CTT GTT GAT AGC ATC TTC AGC TAT AGC TTC GAC 
AGG ATT CAT ACA TCT CTA CCT
TA TGG AGC ACA AGG AGG CTG TGC AAA CTG TTG TGA 
CAT AGT GGC TGT GGC TGC TGC CAG ACG GCT ATC CAC 
TAA ACT GCT GGT AGA GTT GTG ACT TCA TAG TGT CTA 
TAGTCATAGTCAAC
T ATT GGA GCA CAA GGT AGG GGG AGG AGG AGG AGG 
GTA TTG GTA GGC AGT CTG CCC ATG TTA CTA TCA TAT 
TGT AGC TCG AGC TGT CAC TTT GCA TCA
T GGC TCC TTG GTG CTG CAT GAC CTA TGC TCT GAG GCA 
ACA AGG AAA CTG TGTC CCT TGC CCT TCC AGA TGT AGC 




















Pro A l-C r 
(Creverse)
Pro A l-C r  
(Creverse)











ATCC AGGTGCTTCTC AGCGATTTCC ATGGCC AGGTT AAT AT
TTCCTATGGGGTCATCCTTGTTAAGCTTTGAGTAGTCAATG
AGGTCAGGCCGGTGTCGGTGGATGAGGGCACAGAGTCAA























GNGGTGTAGNTGATCNGNCGCNGTNANCTGNCT AGT ATT C
AGTNNGGCTTTCAACA






Search Program Similarity Search Results*
Deg Cl-Dr 700 Tblastx 95% Homo sapien cDNA clone h03001 5’ end similar
(forward) to Glutathione S transferase T19407
Deg Cl-Dr 600 Tblastx 56% Homo sapien STS genomic sequence, sequence
(reverse) G51046
Blastn no significant topo similarity
Deg Cl-Dr 575-1 Tblastx 99% homo sapien cDNA clone N54001
(forward)
Prositescan 57% similarity topo Q signature
56% similarity Pro topo I signature
Deg Cl-Dr 575-1 Tblastx no significant similarity
(reverse)
prositescan no pattern similar
Deg Cl-Dr 575-6 prositescan 51% similarity topo Q signature
(forward) 60% similarity Pro topo I signature
58% similarity Euk topo I signature
blastn 96%similarity to human nu-topo IU07804
Deg Al-Cr 900 blastn 97% similarity to Amyloid Beta Protein precursor
(reverse)
Deg Cl-Dr 290-2 blastn 95% human rectifier potassium channel 4 HS434P1
(reverse)
tblastx 90% Soares fetal liver spleen 1NFLS SI Homo
sapiens cDNA clone AA677969
prositescan Camp- & cGMP-dependent protein kinase (PK)
phosphorylation site, PKC phosphorylation site, N-
myristoylation site
Deg Cl-Dr 290-3 blastn 95% human DEAD-box protein p72 U59321
(reverse)
prositescan no significant topo similarity
Exact Al-Cr 1100 blastn 94% similarity to human DNA topoisomerase I
(forward)
Pro Al-Cr 575 tblastx/blastn no significant similarity
(forward)
Pro Al-Cr 425 tblastx/blastn no significant similarity
(forward)
Pro Al-Cr 450 tblastx 96% similarity to CX-actinin
(forward)
topo H 5’lr 400 blastn no significant similarity
in ) ...........
“based on e value = expectation value, the number o f distinct alignments with scores equivalent or better 
than the one o f interest, that are expected to occur in a database search purely by chance, ie. the lower the 
e value, the more significant the score is. E values less then le"* were considered significant
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Similarity Searches
Each RT-PCR product sequence was subjected to database searches and sequence 
alignments. The tblastx search program was used more frequently then other search 
programs because it was specifically designed to find distantly related genes. Similarity 
significance was dependent upon the expectation value (e value) of a match. The 
expectation value is a parameter that describes the number of hits one can expect to see 
by chance when searching a database of a particular size. The e value is a convenient 
way to create a significance threshold for reporting similarity results (79). Similarity 
search results can be seen in Table 16. A brief description of BLAST programs used can 
be seen in Table 19.
The search tool PROSITESCAN was used to scan protein sequence for 
occurrence of core patterns of known protein families (90). The Prosite database consists 
of protein families and domains that include biologically significant regions such as 
catalytic sites, prosthetic groups, metal binding sites, and molecule binding sites. As 
shown in Table 16, a PROSITESCAN usually accompanied a BLAST search if 
inadequate information was attained at the BLAST level. Table 17 shows topoisomerase 
consensus patterns. Table 18 shows which frame, out of a six frame translation of 
nucleotide sequence, possessed topoisomerase pattern similarity.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
76
TABLE 17
Prosite Topoisomerase Consensus Patterns
Protein Family/Domain Prosite Consensus Pattern8
Eukaryotic DNA [DEN]-x(6)-[GS]-[IT]-S-K-x(2)-Y-[LIVM]-x(3)-
Topoisomerase I Active Site [LIVM],
Prokaryotic DNA [EQ]-x-L-Y-[DEQT]-x(3,12)-[LI]-[STl-Y-x-R-
Topoisomerase I Active Site [ST]-[DEQS]
DNA topoisomerase II [LIVMA]-x-E-G-[DN]-S-A-x-[ST AG]
signature
‘Amino acids contained in square brackets indicate any one amino acid at that position. X represents any 
amino acid. Numbers in parentheses indicate the number o f  X’s possible at that position.
TABLE 18
Prosite Search Results
Sample Translation Frame % Similarity Amino Acid Sequence8
575-1 5'3' Frame 2 57% DNA topoisomerase 
II signature
LNsGNSyHx
5'3' Frame 3 56% Prokaryotic DNA 
topoisomerase I active site
xGLYpAHHCPILFFLTI
SvExTS
575-6 5'3' Frame 2 51% DNA topoisomerase 
II signature
sQEGxtAKv
5*3* Frame 3 60% Prokaryotic DNA 
topoisomerase I active site
kELtaPDENEPAKILSYN
RaS
3'5' Frame 1 58% Eukaryotic DNA 




3'5' Frame 3 50% Prokaryotic DNA 
topoisomerase I active site
hCmYEYLGCLalLRSx
‘Amino acids shown in capital letters represent exact matches to the specified protein domain. E values less 
then le*7 were considered significant
The program LALIGN was used to eliminate the possibility that the putative mt- 
topo I sequence obtained, 575-1, was not one o f the two human type I topoisomerase 
pseudogenes. 575-1 had a 57% identity score in a 199 nucleotide overlap with human
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topoisomerase pseudogene 1 and a 55% identity score in a 194 nucleotide overlap with 
human topoisomerase pseudogene 2. 575-6, which is 96% homologous to nu-topo I, had 
a 96% identity in 1805 nucleotide overlap with pseudogene 1, and a 95% identity in 1229 
nucleotide overlap with pseudogene 2. 575-1 was not one of the two human type I 
topoisomerase pseudogenes.
LALIGN was also used to determine the percent identity of 575-1 to a 
prokaryotic type I topoisomerase, E  coli topA gene, and a eukaryotic type I 
topoisomerase, human nu-topo. There was a 56% identity match in a 157 nucleotide 
overlap to the E. coli topA gene and a 57% identity match in a 200 nucleotide overlap to 
the human nu-topo I. Due to the greater than 50% similarity of 575-1 to both a 
prokaryotic and eukaryotic type I topoisomerase, but otherwise being uncharacterized, 
575-1 was used as a probe to screen a human liver cDNA library. A northern blot was 
performed to determine the size of the 575-1 message. A type I topoisomerase conserved 
motif analysis and the phylogenetic relationship of 575-1 to known type I topoisomerase 
species were also conducted.
TABLE 19
BLAST Programs Used





Not intended for finding 
distantly-related coding 
sequences, parameters 
optimized for speed 
Very useful for preliminary 
data, translates DNA query
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MEME
To further characterize the putative mt-topo I fragment, 575-1, and the other RT- 
PCR products generated from the C-D primer set, the bioinformatics program MEME 
was utilized. MEME finds conserved motifs in a group of unaligned sequences. 
Sequence information of RT-PCR products generated from the degenerate primer set, C- 
D, which flanks the type I topo catalytic domain, were analyzed along with seven known 
eukaryotic type I topo species. This allowed a comparison of RT-PCR sequence 
fragments against full-length topo sequences to see if any conserved motifs existed 
between them. It was interesting to see if the RT-PCR products contained any of the type 
I topo motifs found. More specifically, the sequences MEME analyzed for conserved 
motifs were HUMTOPI (human type I topo), XELTOPOIS (frog type I topo), 
DROTOPISO (drosophila type I topo), YSCTOPI (yeast type I topo), CETOPOI (C. 
elegans type I topo), MUSTOPI (mouse type I topo), CGDNTPIIB (Chinese hamster type 
I topo), and six RT-PCR products, CD575-1, CD575-6, CD290-2, CD290-3, CD700, and 
CD600.
MEME found six motifs. To determine what these motifs were, each motif was 
subject to a blastn search. A prositescan was also performed using the motifs translated 
sequence. In all six motifs, type I topoisomerases were detected in blastn searches. In a 
few cases, other seemingly unrelated proteins were detected. Motif sequence information 
and RT-PCR products included in the motif can be seen in Table 20. Table 21 shows 
motif blastn and prositescan search results.




Motif DNA Sequence RT-PCR Sequences
# Included in Each Motif*
1 5’ TTC CGT ACA TAC AAT GCC 
TCC ATC ACA CTA CAG CAG 
CAG CT 3’
2 S’GCCCTGGGAACCTCCAAACTC 
AATT ATCTGGACCCT AGGATC A 
CAGTGGCATGGTG 3’










6 5 ’ GC AG AT ACTGTGGGTTGTTGC
__________ TCACTTCGAGTGGAGCACAT3’ _____
‘All seven known topo species were found in each motif. RT-PCR scores are listed in parentheses. 
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TABLE 21




1 blastn 97% Homo sapiens type I DNA 
topoisomerase gene, exon 17; 
95% Human clone 798A17
prositescan N-glycosylation site, Casein kinase II 
phosphorylation site
2 blastn 99% Homo sapiens type I DNA 
topoisomerase gene
prositescan PKC phosphorylation site
3 blastn 100% C. griseus topo I,
94% % Homo sapiens type I DNA topo
prositescan Tyrosine Kinase Phosphorylation site
4 blastn 97% Human topoisomerase pseudogene 1
prositescan N-glycosylation site
5 blastn 98% Mouse topo I mRNA complete cds, 
96% Human topo I mRNA, exon 13
prositescan Casein kinase II phosphorylation site, 
PKC phosphorylation site
6 blastn 91% Human topo I, exon 15
prositescan Casein kinase II phosphorylation site, 
PKC phosphorylation site
-  ■ —  i — . . .  p  i —«■ — ■ i ■■ *  ii
*For blastn searches, E values less then le  were considered significant.
Motif 1 included RT-PCR products, 575-6 and 290-3. A blastn search of motif 
1 against the NR database resulted in 97% similarity to Human topo I, exon 17. Motif 1 
was also 95% similar to a human DNA clone 798A17 on chromosome lq24 that contains 
the 3’ part o f the FMOl (Flavin-containing Monooxygenases) gene and the FM04 gene, 
three pseudogenes of High Mobility Group protein gene 1, DNA topoisomerase I, and a 
Signal Recognition Particle. 575-6 (96% similar to human nu-topo I), as expected, 
scored higher in relation to motif 1, then CD 290-3 (95% similar to human DEAD-box 
protein). Motif 3 included CD 290-2 (95% similar to human inwardly rectifying 
potassium channel), although 290-2 scored -3.5 times lower than the human nu-topo I
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sequence. Motifs 2, 4, 5, and 6 did not contain any of the RT-PCR generated products. 
CD575-1, CD600, and CD700 were not found in any of the 6 motifs. The type I 
topoisomerase catalytic domain was not detected by MEME. The weak homology of the 
six RT-PCR products as compared to the seven known type I topoisomerase species may 
have interfered with producing an accurate depiction of topo I motifs.
Phylogeny Tree (dnapars)
An unrooted phylogeny tree of seven known eukaryotic type I topoisomerase 
species C-D domains and degenerate C-D RT-PCR products was constructed. The 
distance matrix used to calculate divergence time between species is shown in Table 22. 
The lower the number, the more closely related the 2 sets of nucleotide sequence. The 
tree (fig. 30), which is a diagrammatic representation of the distance matrix data seen in 
Table 22, was constructed to show the overall evolutionary relationship of known type I 
topoisomerase species C-D domains as compared to type I topo RT-PCR products 
generated using the degenerate C-D primer set
As expected, Chinese hamster and mouse topos was more closely related to each 
other than to the other fragments, possessing a low distance ratio of 0.021. The humtopl 
was most closely related to xeltopol (0.302). 575-6 was more closely related to cetopol 
(0.575), than to the human topo I (2.13). Although 575-6 was found to be 96% similar to 
the human nu-topo I in a BLAST search, cetopol was the next most closely related 
known eukaryotic topoisomerase after xetopol to humtopol (1.51). 575-1 was most 
closely related to 290-2 (rectifier potassium channel, 1.27). 290-3 (DEAD box
protein/ATP dependent RNA helicase) was most closely related to ysctopl (1.89). 700 
(glutathione-S-transferase) was most closely related to cetopol (1.82). Although the mt-
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topo I gene was not detected, type I topoisomerase-related domains were found in 
rectifier potassium channel, DEAD box protein/ATP dependent RNA helicase, and 
glutathione-S-transferase.
TABLE 22
Phylogeny Tree Distance Matrix*











HU 0.102 0.112 0.0
M
XE 0.295 0.333 0.302 0.0
CE 1.51 1.33 1.51 1.83 0.0
575- 1.987 2.16 2.14 2.10 0.575 0.0
6
600 3.042 3.17 2.56 2.42 1.20 128 0.0
290- 3.838 3.72 4.60 4.77 1.69 1.41 2.67 0.0
3





2.36 2.49 2.74 2.77 1.61 2.01 4.45 2.88 1.27 0.0
6.06 6.06 5.71 6.06 1.82 2J2 2.39 3.63 3.48 424 0.0
DRO 3.19 2.90 3.18 3.10 5.52 2.62 356 6.06 1.77 3.55 3.49 0.0
YSC 1.79 1.86 2.00 2.38 2.68 3.12 6.06 1.89 2.87 5.75 5.00 3.45
‘The distance is a maximum likelihood estimate of the divergence time (total branch length) between the two 
sequences.











FIG. 30. Eukaryotic type I topo unrooted phylogeny tree.
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An unrooted phylogeny tree was also developed for RT-PCR products generated 
from the prokaryotic topo primer set, A-C, and three known prokaryotic topoisomerases 
(fig. 31). Since RT-PCR products 425 and 575 were uncharacterized, it was interesting 
to see how related or unrelated they were to known prokaryotic topos. There was a closer 
relationship between a-actinin (AC450) and the bacillus topo strains (BACTO, 
BACSMF) as compared to the other prokaryote topo, E. Coli (ECTOPA). AC 425 and 
AC 575 were both distantly related to the known pro topos. Prokaryote conserved topo 
domain primers, which were used to generate DNA from human message, failed to 
amplify a protein with topoisomerase characteristics or signature pattern.







FIG. 31. Prokaryotic topo unrooted phytogeny tree.
Northern Hybridization
A northern blot was performed in order to obtain the full-length 575-1 message. 
The putative mt-topo I purified PCR product, 575-1, was used as a probe to screen human 
liver mRNA (Clontech). The DNA probe was random primer labeled using [a-32P]dCTP. 
As shown in fig. 32, a 9 kb message hybridized with the 575-1 probe. Message size was
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determined by plotting RNA MW marker distance migration verses log of each MW 
marker in base pairs (Graph 3). Measurements of distance migrated were taken relative 
to the bottom edge of the formaldehyde/agarose gel.
FIG. 32. Northern blot Autoradiograph depicting 9 kb 575-1 mRNA.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
87
log MW marker (bp)
GRAPH 3. RNA MW marker size vs. distance migrated. Standard curve used to 
determine 9 kb message size.
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Transcript Synthesis/Psoralen-Biot in Labeling
Approximately 6.5 |Jg of RNA was successfully synthesized from 575-1 DNA 
with an absorbance 260:280 ratio of 1.8.
575-1 RNA and DNA probes were successfully biotinylated as shown in figure 
39. The PCR product of interest, 575-1, was cloned into a pGEM vector which contained 
SP6 and T7 promoter regions. RNA could be transcribed from the SP6 promoter using 





FIG. 33. Dot blot of biotinylated 575-1 RNA and DNA probes.
cDNA Library Screen
a. topo I containing genes- Approximately 800,000 plaques were screened. Three cDNA 
screens were performed with 3 different probes.
The first screen used a combination of eukaryotic and prokaryotic primer sets as 
probes (Table 2). The primary screen produced 22 putative positive signals. These 
putative positive clones were then subject to plaque PCR in order to determine if they 
contained conserved eukaryotic or prokaryotic regions. Three out of the 22 positives 
produced plaque PCR products. The secondary screen was performed using the 22 
positives from the primary screen. Twelve positives were detected. Two clones
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produced plaque PCR products. Sample 13C produced a 350 bp Deg. C-D band. 
Sample 20-2 produced 11 products ranging in size from 1.3 kb to 300 bp. Cored positive 
plaques suspended in SM buffer/2%chloroform and stored at 4°C should be stable 
without loss of viability. The plaques, in fact, no longer grew after a few weeks, 
therefore, DNA in significant quantities could not be recovered and sequence information 
could not be obtained.
The second cDNA screening attempt used 575-1 as the probe. An example of 
cDNA library plating is shown in fig. 34. The primary or initial cDNA screen produced 
11 putative positives. A sample autoradiograph from the primary cDNA screen is shown 
in fig. 35. Each positive plaque was cored, regrown on a fresh LB plate, and rescreened. 
This secondary screen produced eight putative positives (fig. 36). The tertiary cDNA 
screen produced six positives (fig. 37).
These six were then subject to plaque PCR reactions in order to determine if they 
contained 575-1. A 575-1 left and right primer set was used to amplify an expected 274 
bp product of 575-1 (fig. 29, diagram). As shown in fig. 25, clone 6A was the only one 
to produce a band at the expected size. Clones 6A appeared to contain the amplified 
region of 575-1.
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FIG. 34. cDNA library plating: serial dilution.
FIG. 35. Primary 575-1 cDNA screen positive. Positive clone circled.
(dots at edge o f  membrane mark needle pokes for LB plate orientation)
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FIG. 36. Secondary 575-1 cDNA screen positive. Positive clones are circled.
FIG. 37. Tertiary 575-1 cDNA screen positives. Arrows indicate positive signals.
b. topo II containing genes- The initial cDNA library screen using topo II probes (Table 
3) produced 30 putative positives. These were recovered from the original plate, 
replated, and rescreened. Although many of these proved to be false positives, nine 
produced positives at the secondary screen level. Out of these nine, six were still viable 
to continue on with a tertiary screen. The tertiary screen failed to work, resulting in no 
detectable positive signals. Plaque PCR was then used to screen putative positives from 
the secondary screen. Topo II primers used are shown in Table 4. Topo II primers were 
used with the hope o f amplifying expected nu-topo II regions so as to eliminate these
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clones as prospective mt-topo II candidates. Fig. 25 shows plaque PCR results for two 
putative topo II cDNA screen positives, 10-2 and 19-1 A.
Fluorescence In Situ Hybridization
Fluorescence In Situ Hybridization (FISH) experiments were performed with a 
mixture of purified RT-PCR products ranging in size from -800-200 bp using degenerate 
A-C and C-D primer sets. No distinct signals were discerned due to high background 
levels.
3 'Rapid Amplification o f  cDNA Ends
This system was used for its ability to amplify rare messages for which little 
sequence information is available. Three gene specific primers (GSP) were used, 575- II, 
575-1l nested primer 1, and 575-1L nested primer 2 (diagram, fig. 29). 575-Il occurred 
at base pair position 61 out of the 410 bps sequenced of 575-1. 575-Il nested primer 1 
occurred at base pair position 321, ie. 260 bps downstream of 575-Il. 575-Il nested 
primer 2 occurred at base pair position 277, ie. 210 bps downstream of575-lL.
Lane 2 ^
500 ^
FIG. 38. 3’ RACE using 575-Il (gene specific primer). Lane 1, 100 bp MW Marker, 
highest band is 1.5 kb; lane 2 ,3 ’ RACE product
The 575-Il primer produced an -1.4 kb 3’ RACE product (fig. 38). The 575-Il 
nested primer 1 produced an -1.3 kb 3’ RACE product (fig. 39). Sequencing attempts of 
this product failed due to possible contamination of comigrating products. Cloning
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attempts of these products also proved unsuccessful as is described in more detail later in 
this section.
FIG. 39. 3’ RACE using 575-Il nested 1 (gene specific primer). Lane I, 100 bp MW 
Marker, highest band is 1.5 kb; lane 2 ,3’ RACE product
After repeated failed attempts to reproduce products synthesized from 575-1L and 
575-Il nested primer 1, the 575-Il nested primer 2 was developed. The 575-Il nested 
primer 2 had a Tm which more closely matched the Tm of the right universal amplification 
primer used in the 3 ’ RACE kit In addition to having a matching Tm value, the second 
nested primer was longer in length, being a 25-mer verses a 20-mer. The 25-mer was 
hoped to provide more specificity when PCR amplifying from the 1.4 kb 575-Il 
generated 3 ’ RACE product . The 575-1L nested primer 2 produced a -1.2 kb PCR 
product (fig. 40). The -1.2 kb product was purified and used as a template in cycle 
sequencing reactions with 5’ end labeled nested primer 2 or nested primer 1. Two 
sequencing attempts were conducted at low annealing temperatures and varying salt 
concentrations for each primer. No legible sequence was produced.
3 ’ RACE was performed using 575-Il nested primer 2 and human liver cDNA as 
the template. The hope was that by using a primer set with matching Tm’s the specificity 
of the PCR reaction would increase. Several PCR reactions were performed at various
Lane 2
500 bo ^
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
94
annealing temperatures and Mg2* concentrations. Even at an annealing temperature as 
high as 63°C and using a range of Mg2* concentrations, a few distinct products and 
smearing were evident Smears indicated the production of several products at varying 
sizes due to nonspecific priming. Since the PCR parameters could not be optimized for 
the production of a single product, the PCR reactions were run on an agarose gel and the 
expected size fragment excised and purified. Attempts were then made to sequence these 
purified products directly, and to further purify by ligation into a pGEM vector, followed 
by transformation into JM109 competent bacterial cells.
Failure to produce sequence information was thought to be due to dirty template, 
insufficient template, and/or poor annealing of the primer template. Annealing 
temperature adjustments were made below the temperature used to produce the PCR 
product. The template concentrations used were well beyond recommended amounts as 
suggested in the finol DNA sequencing system technical manual. Dirty template was 
believed to be the most likely reason due to contamination of comigrating products. 
Cloning efforts were performed with the hope of alleviating this problem.
Lane
500 bp
FIG. 40. 3’ RACE using 575-lL nested 2 (gene specific primer). Lane 1, 100 bp MW 
Marker, highest band is 1.5 kb; lanes 2 and 3, purified ~1 kb 3’ RACE product
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Cloning attempts of these products also proved unsuccessful. The ligation 
reaction may have been inhibited by sodium iodide carried over from the agarose gel 
slice purification. A different purification kit (Qiagen Qiaquick) was then used that did 
not contain sodium iodide. In addition, the insert to vector ratio was increased to 6:1 and 
the ligase concentration quadrupled. Although several white colonies were observed with 
a low percentage of blue, recombinants isolated from rapid plasmid preparations 
appeared to contain no insert Recombinants were difficult to see due to RNA 
contamination. To confirm insert was not incorporated, PCR was performed on RPP 
samples and from colonies directly picked; ie. colony was picked with a sterile toothpick, 
resuspended in water, boiled for 5 minutes, and quick cooled on ice (fig. 41). PCR 
products from white and directly picked colonies near expected insert size were purified 
(fig. 42) and used in cycle sequencing reactions. In fig. 42 lane 2, three products were 
amplified from a blue colony RPP. These serve as a negative control representing DNA 
generated from the vector or from bacterial genome contamination. The -850 bp 
product, produced from a white colony RPP, seen in lane 3 was a potential insert, since it 
was a different size than the negative control. This product was isolated for sequencing. 
White colony RPP depicted in lanes 4, 5, and 7 produced no products. This could be 
due to the fact that no DNA was recovered in the original RPP. DNA bands of RPP 
samples were difficult to see due to RNA contamination. The -1.1 kb products seen in 
lanes 6,8, and 9 were isolated and purified for sequencing.
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FIG. 41. PCR products using 575-1 nested 2 on RPP samples and direct colony picks. 
Lane 1, 100 bp MW marker, lane 2, blue colony RPP; lane 3-7, white colony RPPs; lane 
8, direct colony 1; lane 9, direct colony 2.
Lane 1 2 3 4 5
FIG. 42. Purified RPP and colony PCR products. Lane 1, 100 bp MW marker, lane 2, 
figure 47/lane 8; lane 3, figure 47/lane9; lane 4, figure 47/Iane6; lane 5, figure 47/lane 3.
Purified PCR products were used in sequencing reactions at 41°C and 37°C 
annealing temperatures with 10 to 4 times the amount of recommended template. Despite 
changes in annealing temperature and template concentration, sequence information was 
not obtained.





In terms of the mt-topo I proteins mechanistic characterization, a 5’ 
phosphotyrosine linkage to cleaved DNA was determined by cleavage assay and 
confirmed by the exonuclease III assay. In the 3’ end labeled cleavage assay, aggregated 
mt-topo cleavage products were unable to enter the agarose gel in the absence of 
proteinase K (PK) (fig. 12, lane 5). Addition of PK resulted in migration of numerous 
cleavage products into the gel (fig. 12, lane 6). When the topoisomerase was removed 
from the 5’ end by digestion with proteinase K, cleavage products were free to migrate. 
This showed that the topoisomerase was linked to the 5’ end of the cleaved DNA. The 
presence of the enzyme on the 5’ end of DNA was catenating or holding broken strands 
together, causing them to form one large structure which could not pass through the 
agarose gel.
The nu-topo I is known to covalently link to the 3’ phosphate of a phosphodiester 
bond when cleaving DNA (16, 80). The prokaryotic top I links to the 5’ phosphate o f 
cleaved DNA (81, 82). The ability of mt-topo I’s to link to the 5’ end of cleaved DNA not 
only serves as a discerning mechanistic difference between the nu-topo I and the mt-topo 
L, but also suggests a closer evolutionary link of the mt-topo I to prokaryotic type I 
topoisomerases. Future attempts to isolate the mt-topo I gene should include a more 
extensive selection of prokaryotic topo primers for use in RT-PCR.
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A problem encountered in performing the cleavage assay was the inability of the 
mt-topo I to cleave due to its low storage concentration. The enzyme was dialyzed in the 
hope of concentrating the topoisomerase. Dialysis, itself proved risky, because 
topoisomerase activity could be lost altogether.
As for the K+SDS' precipitation experiment, high background counts were 
detected. The high background counts suggested that the radiolabeled DNA was able to 
interact with the K+SDS" without the presence of the topoisomerase. Bovine serum 
albumin (BSA) contained in the assay cocktail and/or the use of too high a concentration 
of SDS may have contributed to the problem.
Drug inhibition studies were also performed to further distinguish the mt-topo I 
from its nu-topo I counterpart DMSO, berenil, and seven antimicrobial/anti fun gal drugs 
were studied. DMSO and berenil have previously been found to discriminate between 
the nuclear and mitochondrial type I topoisomerases isolated from rat liver and calf 
thymus (75). My study looked at differences in DMSO and berenil sensitivity of type I 
topoisomerases isolated from calf liver.
In terms of the DMSO inhibition assays, less inhibition was observed than 
expected for the mt-topo I in the presence of 5% DMSO, 29% verses 60 % inhibition. In 
the presence of 20% DMSO, mt-topo I did correlate with previous results displaying high 
levels of inhibition.
The nu-topo I did not completely correlate with previous studies. The calf liver 
nu-topo I was inhibited 28% as compared to 50 % inhibition in the presence of 20% 
DMSO, and showing a slight inhibition verses no inhibition in the presence of 1%
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
99
DMSO. But, as in the previous study, the nu-topo I displayed some stimulation of 
activity in the presence of 5% DMSO.
Each enzyme followed the overall trends of the previous study. The nu-topo I did 
correlate with previous studies displaying some stimulation of activity the presence of 5% 
DMSO and inhibition in the presence of 20% DMSO. Slightly less inhibition was 
observed than expected for the mt-topo I in the presence of 5% DMSO. In the presence 
of 20% DMSO, mt-topo I did correlate with previous results with activity almost 
completely reduced.
As for the berenil inhibition assays, the mt-topo I exhibited a decrease in activity 
in the presence of 10 pM berenil. Inhibition of mt-topo activity increased when 40 pM 
berenil was added. Inhibition was apparent at the addition of 100 pM berenil, but not 
much more then the 40 pM samples. The nu-topo I, as expected, showed little or no 
inhibition of activity in the presence of berenil.
The slight differences seen in my experiments may be attributed to minor 
structural differences between enzymes isolated from calf liver verses rat liver. As well, 
it was more difficult to quantitate inhibition when observed topoisomerase activities were 
so close to 2 units.
As for the antifungal/antimicrobial agents, only one drug, C l, inhibited the nu- 
topo I in a dose-dependent fashion. The mt-topo I was not inhibited by the drug Cl. The 
drug, Cl, could potentially be used to discriminate between the nu-topo I and mt-topo I. 
More studies need to be performed to extend the preliminary findings with C1.
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GENES CONTAINING TOPO-RELATED DOMAINS
A key technique used in examining topo-related genes was RT-PCR. For each 
eukaryotic topo primer set used, at least one product, representing the known human nu- 
topo I, was expected to be made. Other DNA bands generated were potential mt-topo I 
candidates until proven otherwise by sequencing and computational similarity searching. 
Speculation as .to the types of products generated from the prokaryotic primer sets were 
unknown, due to the fact that prokaryotic primers were being used to amplify from 
human message.
To reduce the problem of nonspecific binding of primers, which could result in 
the synthesis of several bands that did not represent amplified topoisomerase regions, 
annealing temperatures were increased and/or MgCU concentrations varied. Increases in 
annealing temperature forced more specific binding of the primers. Weaker bonds 
formed from mismatches can not successfully anneal at higher temperatures. Since it was 
unknown exactly how related the mt-topo I was to currently characterized type I 
topoisomerases, the decision to use high verses low stringency conditions was difficult 
Amplification of regions due to primer mismatch were undesirable, but too high a 
stringency could eliminate the amplification of the mt-topo I gene.
Another level of specificity or purification was attained through pGEM vector 
cloning. pGEM vector cloning was performed in order to eliminate contamination from 
comigrating RT-PCR products that interfered with obtaining legible sequence. A 
universal primer set that annealed to regions flanking the pGEM vector insertion site 
eliminated problems encountered when trying to cycle sequence using degenerate 
primers. Cycle sequencing with degenerate primer sets was difficult due to the multiple
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primers present that could anneal to more than one area of the template at a time. After 
successfully cloning an RT-PCR product into the pGEM vector, the recombinant plasmid 
DNA was isolated and purified to serve as a template for cycle sequencing reactions.
Rapid plasmid preparations provided a pure, more concentrated stock of an RT- 
PCR product. Single stranded DNA (ssDNA) isolations of pGEM vectors were also 
produced in order to provide a cleaner template source for use in cycle sequencing. 
There was no notable difference in band clarity, as visualized on an autoradiograph, 
between using ssDNA verses double stranded DNA as the template source in cycle 
sequencing reactions.
Overall, thirteen products were generated and sequenced. Seven proved to be 
previously characterized genes. The remainder possessed various enzyme signatures, 
but otherwise, were not completely characterized. Putative mt-topo I RT-PCR products 
were used in various experiments in attempts to further characterize the fragments.
One experiment, Fluorescence In Situ Hybridization (FISH), was performed in 
order to determine the location of the putative mt-topo I gene and/or topo-related genes 
on human chromosomes. The chromosomal location of a putative mt-topo I gene would 
be an important determination to make since the location of the known nu-topo I gene 
and its pseudogenes is already known. A difference in chromosomal location could be 
used to further distinguish the mt-topo I from its nuclear counterpart FISH attempts 
resulted in nonspecific binding of the probe producing a high background. A mixture of 
RT-PCR products were used as probes with their sizes ranging from -200-800 bp. The 
use of a larger probe may have produced a stronger, more concise signal with minimal 
background.
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One RT-PCR product in particular, 575-1, based on similarity search information 
was the most interesting. It possessed a 57% similarity to the topo II signature and a 
56% similarity to the prokaryotic topo I signature in prositescan searches. This putative 
mt-topo I fragment was later used as a probe to screen a human liver cDNA library.
In cDNA library screening, plaque PCR proved to be an instrumental technique in 
confirming positive cDNA clones. It provided a quick and easy means to find topo- 
related genes. By using plaque PCR, potential positive cDNA clones were successfully 
screened for regions that contained an area of sequence related to the primer set being 
studied. Having obtained a positive clone, the next step was to sequence i t  A drawback, 
however, in doing this type of PCR was that the viability of the resuspended plaque was 
finite. Therefore, the integrity of the recombinant DNA rapidly decreased over a matter 
of a few weeks. Unfortunately, as in the topo II and 575-1 cDNA screens, clones of 
interest lost their viability before sequence information could be obtained.
However, some legible sequence information had been obtained from direct 
sequencing of the RT-PCR products. The next step was to identify or characterize them. 
Use of bioinformatics technology was critical to finding topo-related genes. Sequence 
databases and search tools were not only used to characterize RT-PCR products 
generated, but were also used in the beginning stages of the project to design RT-PCR 
primers and cDNA screen probes. Through similarity searching, the putative mt-topo I 
sequence, 575-1, was revealed.
Similarity searching is the process o f comparing a new sequence against all other 
known sequences and then attempting to infer the function of the new sequence by 
assessing the matches (83). Table 16 shows a variety of similarity search results ranging
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from identities in the 90 percentile range to cases of no significant sequence similarity. 
Several explanations may account for cases in which search results indicate no significant 
similarity. This may be due to the use of a sequence query that is too short, inaccuracies 
in reading an autoradiograph, the query sequence not being characterized, or that the 
query sequence contained regions with low-complexity. Regions with low-complexity 
sequence; for example, the nucleotide sequence AAA TAA AAA ATA AAA AT, have 
an unusual composition that can create problems in sequence similarity searching due to 
their ability to produce artificial hits (84). Inaccuracies when reading cycle sequencing 
autoradiographs may also explain lower then anticipated percentile scores; for example, 
96% verses 100% identity, for the expected nu-topo I fragments generated from 
degenerate primer sets.
In an effort to obtain the entire 575-1 gene, a cDNA library screen was performed 
using 575-1 as the probe. Selected cDNA clone positives were believed to represent 
portions of the mt-topo I gene. If the sequence was similar to the nu-topo I and/or a 
topoisomerase pseudogene, yet different, the sequence was a potential mt-topo I gene 
candidate. A dark spot on each of the duplicate lifts represented the hybridization of the 
probe and a particular cDNA. To ensure the dark spot was not a false positive, the 
individual plaque was isolated, replated at a more dilute concentration, and a second 
screen was performed If the signal persisted, and was found in all or most of the 
replated plaques, this cDNA most likely consisted of a portion of the 575-1 fragment 
The cDNA clone was isolated and sequenced using the finol DNA Cycle Sequencing 
System. Several thousands of plaques were screened in order to increase the probability 
of finding the low frequency mt-topo gene. Some false positives were detected due to
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nonspecific interactions. Where false positives were detected, filters were rewashed 
under more stringent conditions, ie. at higher temperatures and/or lower salt 
concentrations to minimize nonspecific binding.
The cDNA screen produced one positive clone. More positive clones were 
expected due to the 9 kb message size, as indicated by a northern blot, and due to the 2 kb 
insert capacity of the Xgtl 1 vector. Attempts to sequence the cDNA screen clone failed 
due to the inability to properly purify the template. Phenol/chloroform extractions, a 
Biorad DNA purification kit, and a Promega lambda DNA purification kit failed to 
produce pure template. Difficulty in sequencing the clone, 6A, was compounded by the 
fact that the phage containing the recombinant would not grow. A possible explanation 
for the lack of growth may be the addition of too much chloroform when resuspending 
the cored plaque in SM buffer or that the protein expressed by this particular recombinant 
had some lethal effect. Because sequence information could not be obtained from the 
clone 6A, 3’ RACE was performed. Since 410 bp of 575-1 had been successfully 
sequenced, the 3’ RACE system was used in the hopes of gathering more sequence from 
the 3’ end of the 575-1 message. The 3’ end of the message was of particular interest due 
to the fact that the eukaryotic type I topoisomerase catalytic domain, D, was contained in 
this region.
3’ RACE was chosen verses S’ RACE also due to the 575-1’s 9 kb message size. 
The 5’ RACE system was not designed to amplify such large messages. Since 575-1 was 
produced from a primer set located near the 3’ end of conserved topoisomerase domains 
(Deg. Cl-Dr), 575-1 was more likely to be found closer to the 3’ end of the message.
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Being closer to the 3’ end of the message would allow for a more reasonably sized 
amplification product.
The 575*1 fragment was closer to the 3’ end, as suspected, because the 3’ RACE 
experiment produced a -1 .4  kb product using 575-Il as the gene specific primer. This 
was confirmed when the primary PCR product was reamplified using the 575-Il nested 
primer 1 which produced a -1 .2  kb product The -1 .2  kb product was around the 
expected size since the 575-Il nested primer anneals 260 bps downstream from 575-Il 
(figure 29, 575-1 primer diagram). The use of a nested primer confirmed that the PCR 
product generated was a specific amplification product representing a portion of the 575- 
1 message. Attempts were made to sequence both the -1 .4  kb and -1 .2  kb products. 
Cycle sequencing directly from purified samples of each resulted in comigrations at 
specific regions of the gel in all four lanes (G, A, T, C) or no bands at all. These results 
suggested contamination of a similarly sized fragment in the purified samples or dirty 
template. To circumvent these problems, attempts were made to ligate the 1.4 kb 3’ 
RACE product into a  pGEM vector. By successfully creating this clone, the 
contamination problem would have been eliminated because only one fragment can be 
inserted into each vector at a time. In addition, the clone would have provided an easy 
means to generate more template as needed. Repeated cloning attempts proved 
unsuccessful. Although positive control samples were successfully ligated, increases in 
ligase concentration, template concentrations, and incubation periods did not ligate the 3 ’ 
RACE product samples.
Bioinformatics technology was used to further characterize the 575-1 sequence 
information available. The program, MEME, was used to search for motifs or consensus
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sequence patterns from a pool of seven known eukaryotic type I topoisomerase species 
and six RT-PCR products. The goal was to determine if any of the RT-PCR products 
possessed shared motifs in common with the already characterized topo species. Only 
three, 575-6, 290-2, and 290-3 possessed some similarity to six motifs found by the 
program. 575-6, which represents a portion of the human nu-topo L, was expected to be 
included in a motif. 575-6 was found in motif 1 possessing a relatively high score. 290-3 
was also grouped with motif 1, but had a low relative score. Motif 1 was found to be 
homologous to exon 17 of the human nu-topo I. The 290-3 result was interesting because 
similarity search results revealed it to be the human DEAD-box protein, p72. P72 is a 
novel human member of the DEAD box family of putative RNA-dependent ATPases and 
ATP-dependent RNA helicases (85). Although 290-2 had a low score in relative 
comparison to the other sequences, 290-2 had some similarity to motif 3. This was 
surprising since blast search results indicate that 290-2 to be the human inwardly 
rectifying potassium channel J4. 575-1 was not found in any of the six motifs. Although 
the mt-topo I gene was not detected, type I topo-related proteins were found: DEAD-box 
protein, human inwardly rectifying potassium channel J4, and glutathione-S-transferase.
In addition to a consensus sequence analysis, a comparison at the molecular 
evolutionary level was investigated. The purpose was to determine if a relationship, if 
any, existed between known type I topo species and the RT-PCR products. The program, 
dnapars, was used to construct an unrooted phylogeny tree of the seven known 
topoisomerase species C-D domains and six RT-PCR products generated using the 
degenerate C-D primer set A tree was also constructed for three known prokaryotic 
topoisomerases and three RT-PCR products generated from a prokaryotic topo primer set
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In the eukaryotic tree, 575-6, was the most related to the known topoisomerase, 
CETOPOI. 575-1, on the other hand, was the most related to the RT-PCR product 290-3 
(DEAD box protein). In the prokaryotic tree, none of the RT-PCR products were 
significantly related to the known prokaryotic topo species. Prokaryote conserved topo 
domain primers, which were used to generate DNA from human message, failed to 
amplify DNA products encoding a protein with topoisomerase characteristics or signature 
pattern.
Another piece of evidence to further characterize 575-1 was obtained from a 
northern blot The large 9 kb message size, in addition to the distant relationship to 
known eukaryotic type I topoisomerase species indicated that the 575-1 putative mt-topo 
I fragment was highly unlikely to be part of the mt-topo I gene. A literature search 
indicated no known topoisomerase possessing a message of that size. A typical type I 
topoisomerase message is around 3 kb. Prositescan results o f 575-1 contained 105 other 
enzyme patterns in addition to the topo signature patterns when the stringency of the scan 
was set to 50% similarity. A literature search was performed looking for a correlation 
between a 9 kb message and any of the other enzyme patterns seen on the prositescan. 
Only 2 patterns, an N-giycosylation site and a tyrosine kinase phosphorylation site, had 
proteins associated with these signatures that possessed a 9kb message. They were a 
human pre-sialomucin complex (membrane-associated glycoprotein) and a human trkB 
receptor (membrane-associated tyrosine kinase receptor). 575-1 may represent a portion 
of these proteins.
575-1 is not the mt-topo I gene. The putative mt-topo I fragment, 575-1, 
possessed a message size three times the size of known type I topoisomerases, contained
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none of six type I topoisomerase motifs, and was distantly related when compared to 
seven characterized eukaryotic type I topoisomerase species in the unrooted phylogeny 
tree.
In conclusion, the mt-topo I gene is fundamentally different from known 
eukaryotic type I topoisomerases. Degenerate primers developed from eukaryotic type I 
topoisomerase conserved domains were not able to amplify a region of the mt-topo I 
gene in RT-PCR reactions, although the known nu-topo I was detected. Future 
investigations should include a more thorough development of prokaryotic type I 
topoisomerase primers.
FUTURE DIRECTIONS
In order to find the mt-topo I, better primers and probes need to be developed. 
The motif information generated from the MEME program may be used to design 
varying primer sets for use in RT-PCR. In addition, further investigation into 
prokaryotic type I topoisomerases primer sets should be conducted. The mt-topo I, as 
indicated by its 5’ covalent linkage to cleaved DNA, possesses prokaryotic 
characteristics as well as eukaryotic. Recent evidence indicates the obligate anaerobe, 
Rickettsia, to be the closest known eubacterial relative of the mitochondria (86). Further 
investigation of the rickettsia genome should be conducted for RT-PCR primer 
development
In future RT-PCR reactions, if  a DNA sequence of interest does arise, the putative 
mt-topo I gene may be verified by translating its cDNA and assaying for mt-topo I 
activity. The active protein would be expressed in bacterial cells. A bacterial system
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would be preferred due to the fact that the bacterial topoisomerase and mt-topo I activity 
can be easily distinguished from one another in a standard topoisomerase relaxation 
assay. To distinguish endogenous bacterial topoisomerase activity from recombinant 
topoisomerase activity the relaxation assay would be performed in the presence and 
absence of Mg2+ A potential difficulty or limitation may be that some recombinants may 
express low levels of proteins making it difficult to detect enzyme activity. To further 
distinguish the mt-topo I from the bacterial topo I, a western blot would be performed 
using a topoisomerase specific antibody that recognizes the mitochondrial but not the 
bacterial topoisomerase. Topoisomerase-specific antibody has been found to recognize 
both the nu-topo I and the mt-topo I (35).
The pET E. coli expression system (Stratagene) can be used. The pET E. coli 
expression system is a widely used in vivo bacterial expression system, due to the strong 
selectivity of the bacteriophage T7 RNA polymerase for its cognate promoter sequences, 
the high level of activity of the polymerase, and the high level of efficiency of translation 
mediated by the T7 gene 10 translation initiation signals (87, 88). In the pET system, 
protein coding sequences of interest are cloned downstream of the T7 promoter and gene 
10 ribosome binding site, and then transformed via electroporation into E  coli. The 
coding sequence for the putative mt-topo I will be processed for adding BamHI linkers to 
the ends, followed by insertion at the BamHI cloning site in the pET3b expression vector. 
The pET3b recombinant plasmid will be transformed into E  coli cells with protein 
expression achieved by IPTG induction of a chromosomally integrated cassette in which 
the T7 RNA polymerase was expressed from the lacUV5 promoter (89). Upon induction, 
the highly active polymerase will produce an abundant number o f transcripts with the
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target protein constituting the majority of the cellular protein after a few hours. E. coli 
cells will be harvested and stored at -70 °C. The bacterial cell paste will be thawed and 
lysed by the presence of endogenous T7 lysozyme. The cell lysate will then be 
centrifuged to remove cell debris and tested for mt-topo I activity. Successful mt-topo 
synthesis will be determined in two ways: using a standard topo relaxation assay, and via 
immunodetection of the mt-topo I protein expressed in bacterial cells to topoisomerase- 
specific antibody.
To perform the western blot, bacterial cell lysates expressing the mt-topo I protein 
will be run on a polyacrylamide gel, the separated proteins will then be transferred to 
nitrocellulose, and incubated with topoisomerase-specific antibody. Recognition of the 
antibody to the mt-topo I protein will be detected on the blot by using an enhanced 
chemiluminescence system (ECL, Amersham) which incorporates Protein A-linked 
horseradish peroxidase. The western blot will be performed on bacterial cells not 
containing the mt-topo I protein expression vector. Since bacterial cells do not express 
the nu-topo I, one would expect to get no detection using the topo-specific antibody. 
This negative result can be compared to an expected positive result when using cells 
containing the mt-topo I expression vector. By probing with an antibody that recognizes 
both the nu-topo I and the mt-topo I in a bacterial system where nu-topo I does not exist, 
any observed topo I activity present in the absence of Mg2+ would provide further 
evidence that distinguishes the mitochondrial topoisomerase from its nu-topo counterpart.
To ensure expression of the full message, cDNA insert sizes will be compared to 
the full length message as obtained via northern blot Expression of a partial message
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may explain low levels or lack of mt-topo I activity in topoisomerase relaxation assays or 
lack of detection in western blots.
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APPENDIX A
MITOCHONDRIAL PREPARATION FROM CALF LIVER
1. Trim the fat and grind fresh calf liver.
2. Suspend the ground volume in 6 volumes (w/v) of IX MIB (0.04 M Tris, 0.25M 
sucrose, 0. ImM EDTA) and blend in a blender with a 10 seconds on and offburst twice.
3. Centrifuge for 2000 g for 30 minutes.
4. Collect the supernatant and centrifuge at 8500 g for 35 minutes.
5. Collect the pellets and homogenize in 6 volumes (v/v) of IX MIB.
6. Homogenize in a final volume o f600 mL per kg of the liver with IX MIB.
7. Apply 80 mL of the crude mitochondrial suspension to a two-step sucrose gradient 
composed of 75 mL of 25% sucrose in TE and 90 mL of 42.5% sucrose in TE.
8. Centrifuge at 26,000 g for 75 minutes.
9. Collect the banded mitochondria at the interface of the two sucrose layers.
10. Dilute with 2 volumes of TE and centrifuge at 22,000 g for 20 minutes.
11. Collect the pellets and homogenize in 6 volumes of IX MIB.
12. Determine the mitochondrial protein suspension by Biuret analysis.
13. Add 1 mg of digitonin per 8 mg of mitochondrial suspension and stir occasionally for 
15 minutes on ice.
14. Dilute with 2 volumes of IX MIB.
15. Centrifuge at 10,000 g for 15 minutes.
16. Collect the pellets and homogenize in 6 volumes of IX MIB.
17. Repeat step 15.
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18. Collect the pellets and homogenize in 100 mL per kg of liver with 50 mM Kpi 
(potassium phosphate)/0.1 M KCL/15% glycerol for direct lysis.
19. Add Nonidet P40 to the mitochondrial suspension to a final concentration of 1%.
20. Collect the supernatant as SI.
21. Homogenize the pellet with PiK-1.0 (50 mM Kpi/1.0 M KCL/15% glycerol).
22. Stir for 30 minutes on ice.
23. Centrifuge at 250,000 g for 3 hours. Collect the supernatant and label S2.
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APPENDIX B
MT-TOPO I ISOLATION: COLUMN CHROMATOGRAPHY
1. Phosphocellulose (PC) column (3 x 20 cm):
a. pack 12.5 Ml of PC per gram of mitochondrial protein in PiK-0.3 (50 mM 
Kpi/0.3 M KCL/15% glycerol).
b. dilute S2 with PiK-0 (50 Mm/15% glycerol) to 0.3 M KCL.
c. load the diluted sample to the PC column and wash with 3 column volumes of 
PiK-0.3.
d. elute the column with a gradient of PiK-0.3 to PiK-1.5(50 mM Kpi/1.5 M 
KCL/15% glycerol) in a total of 10 column volumes.
e. collect in each fraction one tenth of the column volume.
f. combine the active fractions with more than 4 units (I unit of topo activity = 
amount of activity to relax 50% of plasmid DNA within 30 minutes at 37°C) per pi (PC- 
1).
2. Hydroxyapatite (HA) column (2 x 20 cm ):
a. pack 4 Ml of HA per gram of mitochondrial protein in PiK-0.3 (50 Mm Kpi/0.3 
M KCL/15% glycerol/pH 7.8).
b. dilute PC-1 with PiK-0 to 0.3 M KCL
c. load the diluted sample to the HA column and wash with 3 column fractions of 
PiK-0.3.
d. wash with 3 column volumes of Pi-200 (200 mM/15% glycerol/pH 7.8).
e. elute the column with a gradient of Pi-200 to Pi-1000 (1 M KPi/15% 
glycerol/pH 7.8) in a total of 10 column volumes.
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f. collect in each fraction one tenth of the column volume.
g. combine the active fractions with more than 4 units of relaxing activity per ill
(HA-1).
3. dsDNA-Cellulose (dsDNA-C) column (1x9 cm):
a. pack 1ml of dsDNA-C per gram of mitochondrial protein in Tris-0.1 (50 mM 
Tris-HCL/0.1 M KCL/15% glycerol).
b. dialyze the HA-1 (combined active fractions from HA column) with at least 
200 volumes of Tris-0.1 for 3 hours twice.
c. load the dialyzed sample and wash with 3 column volumes of Tris-0.1.
d. elute the column with a gradient of Tris-0.1 to Tris-0.6 (50 mM Tris-HCL/0.6 
M KCL/15% glycerol) in a total of 10 column volumes.
e. collect in each fraction one tenth of the column volume.
f. combine the active fractions with more than 4 units of relaxing activity per Ml 
(ds-DNA-1).
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